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METHOD OF TREATING ENDOTHELIAL
DYSFUNCTION COMPRISING
ADMINISTRATION OF A THROMBIN
PEPTIDE DERIVATIVE
RELATED APPLICATIONS
This application is the U.S. National Stage ofInternational
Application No. PCT/US2007/020445, which designated the
United States and wasfiled 21 Sep. 2007, was published in
English, and claims the benefit of U.S. Provisional Applica-
tion No. 60/846,418 filed Sep. 22, 2006, U.S. Provisional
Application No. 60/848,004 filed Sep. 28, 2006 and U.S.
Provisional Application No. 60/922,646 filed Apr. 10, 2007.
The entire teachings of the above applications are incorpo-
rated herein by reference.
BACKGROUND OF THE INVENTION
Vascular endothelial dysfunction (ED) is a commoneffect
of aging and is associated with many diseases including
hypertension, coronary artery disease, stroke, cerebrovascu-
lar disease, peripheral vasculardisease, diabetes, erectile dys-
function, atherosclerosis, asthma, rheumatoid arthritis, pul-
monary hypertension, hyperhomocysteinemia, sickle cell
disease, pre-eclampsia, chronic renalfailure, sepsis, and mul-
tiple organ failure. The ability of tissues to repair themselves
in responseto injury or ischemia or to respondto therapeutic
intervention appearsto be greatly diminished because ofED.
Endothelial dysfunction may be due to decreased expres-
sion of nitric oxide synthase (NOS), altered activation of
pathwaysthat block intracellular signaling events, increased
levels of endogenous NOS inhibitors such as asymmetric
dimethylarginine (ADMA), increased degradation or conver-
sion of NO to peroxynitrites (due to high levels of reactive
oxygen species) or increased activity of arginase which con-
verts L-arginine to urea, thereby limiting the availability of
L-arginine as a substrate for NOS.
A numberofrecent studies indicate that arginase plays a
key role in ED and the modulation of NOSactivity by regu-
lating intracellular L-arginine availability. In aging vessels
with ED,for example, arginase is upregulated, but addition of
a specific arginase inhibitor restores endothelial function and
nitric oxide (NO) responsiveness of vessels. Other diseases
where arginase inhibition overcoming ED has been shown
include asthma, where increasedarginase activity contributes
to a deficiency of NO and decreased airway smooth muscle
relaxation, pulmonary hypertension, and spontaneous and
salt-induced hypertension. L-arginine supplementation has
also been shownto reverse ED completely orpartially in a pig
model of hypertension, in dilation defects caused by
ischemia/reperfusion, and has even been shown to improve
walking capability in patients with peripheralarterial disease.
These studies suggest a potential therapeutic role for drugs
that decrease arginase upregulation or control the activity of
arginase in a numberofvascular diseases.
Recent studies have shown that both hypoxia and certain
inflammatory mediators, including TNFa, increase arginase
or decrease endothelial cell nitric oxide synthase (eNOS)
activity. Both prolonged inflammation and chronic ischemia
appear to contribute to ED.
There is a need for methods to treat endothelial dysfunc-
tion, which is responsible for, or contributes to, a great many
diseases and disorders.
SUMMARYOF THE INVENTION
Applicants have discovered that compounds which stimu-
late or activate the non-proteolytically activated thrombin
15
40
45
55
65
2
receptor (hereinafter “NPAR”) can reverse or inhibit endot-
helial dysfunction by blocking the up-regulation of arginase
associated with endothelial dysfunction, and by promoting
the activation or up-regulation of nitric oxide synthase,
thereby increasing the production of nitric oxide. The NPAR
agonist TP508 blocksthe up-regulation ofarginase 1 (ARG1)
induced by TNFa (Example 2). The effect onARG1 expres-
sion was shown to be dose dependent. TP508 treatment also
increases phosphorylation of eNOS in cells cultured under
normoxic (normal oxygen) and hypoxic (1% oxygen) condi-
tions (Example 3). Moreover, TP508 stimulation ofcells pre-
vents hypoxia-induced down-regulation ofeNOSexpression,
to maintain eNOSat a level that remains close to what would
be observedin cells cultured under normoxic conditions. The
effects of TP508 on eNOS phosphorylation are dose depen-
dent.
The present invention is directed to methods oftreating
endothelial dysfunction at a site in a subject in need thereof,
comprising administering to the subject a therapeutically
effective amount of an NPAR agonist, wherein thesite is not
an artery injured by angioplasty, a chronic skin ulcer, a site in
need of osteoinduction or a site in need of cardiac revascu-
larization.
Morespecifically, the invention includes, with the excep-
tions as recited above, methods of treating endothelial dys-
function in a subject, wherein the subject is suffering from
one or more diseases or conditions selected from the group
consisting ofhypertension, congestive heart failure, coronary
artery disease, stroke, cerebrovascular disease, peripheral
vascular disease, diabetes, erectile dysfunction, atherosclero-
sis, asthma, rheumatoid arthritis, pulmonary hypertension,
acute lung injury, chronic obstructive pulmonary disease
(COPD), cystic fibrosis, inflammatory lung disease, hyper-
homocysteinemia, sickle cell disease, pre-eclampsia, chronic
renal failure, chronic renal dysfunction, renal microvascular
disease, hepatic reperfusion injury, neuropathy, Alzheimer’s
disease, thyroid disease, sepsis, thrombosis, multiple organ
failure, inflammatory bowel disease, and radiation damage.
The present invention is also directed to methodsoftreat-
ing endothelial dysfunction at a site in a subject in need of
treatment, comprising administering to the subject a combi-
nation in a therapeutically effective amount, the combination
comprising one or more NPAR agonists and one or more
angiogenic growth factors, wherein the site is not an artery
injured by angioplasty, a chronic skin ulcer, a site in need of
osteoinduction or a site in need of cardiac revascularization.
The inventionis also a methodoftreating endothelial dys-
function ata site in a subjectin need oftreatment, comprising
administering to the subject a combination in a therapeuti-
cally effective amount, the combination consisting essen-
tially ofan agonist ofthe non-proteolytically activated throm-
bin receptor and an angiogenic growth factor, whereinthesite
is not an artery injured by angioplasty, a chronic skin ulcer, a
site in need of osteoinduction or a site in need of cardiac
revascularization.In this method an angiogenic growth factor
and an NPAR agonist are administered to the subject as the
only therapeutically active agents in the combination therapy.
In some embodiments, the NPAR agonist can be adminis-
tered to the subject systemically, and in other embodiments,
can be administered vascularly, and in still other embodi-
ments, can be administered locally or topically.
In one embodiment, the NPAR agonist is a thrombin pep-
tide derivative disclosed herein. More specifically, one throm-
bin peptide derivative comprises the amino acid sequence of
Arg-Gly-Asp-Ala-Cys-X , -Gly-Asp-Ser-Gly-Gly-Pro-X,-
Val (SEQ ID NO:1), or a C-terminal truncated fragment
thereof comprising at least six amino acids. In another spe-
US 8,334,259 B2
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cific embodiment, the thrombin peptide derivative comprises
the amino acid sequence of SEQ ID NO:2: Ala-Gly-Tyr-Lys-
Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X, -Gly-Asp-
Ser-Gly-Gly-Pro-X,,-Val, an N-terminal truncated fragment
of the thrombin peptide derivative having at least fourteen
aminoacids, or a C-terminal truncated fragmentofthe throm-
bin peptide derivative comprising at least eighteen amino
acids. X, is Glu or Gln and X, is Phe, Met, Leu, His or Val. In
another specific embodiment, the thrombin peptide derivative
is the polypeptide SEQ ID NO:3: H-Ala-Gly-Tyr-Lys-Pro-
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-
Gly-Gly-Pro-Phe-Val-NH, (TP508).
In another embodiment, the NPAR agonist is a modified
thrombin peptide derivative disclosed herein. In a specific
embodiment, the modified thrombin peptide derivative com-
prises the amino acid sequence of SEQ ID NO:4: Arg-Gly-
Asp-Ala-Xaa-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val, or a
C-terminal truncated fragment thereof having at least six
amino acids. In another specific embodiment, the modified
thrombin peptide derivative comprises the amino acid
sequence of SEQ ID NO:5: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-
Gly-Lys-Arg-Gly-Asp-Ala-Xaa-X,-Gly-Asp-Ser-Gly-Gly-
Pro-X,-Val, or a fragment thereof comprising amino acids
10-18 of SEQ ID NO:5.
In another embodiment, the NPAR agonist is a thrombin
peptide derivative dimer oftwo thrombin peptide derivatives
disclosed herein. More specifically, a thrombin peptide
derivative of a dimer comprises the amino acid sequence
Arg-Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-
Val (SEQ ID NO:1) or a C-terminal truncated fragment
thereof having at least six amino acids. In another specific
embodiment, the thrombin peptide derivative of the dimer
comprises a polypeptide having the amino acid sequence of
SEQ ID NO:2: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-
Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val, or
a fragment thereof comprising amino acids 10-18 of SEQ ID
NO:2. In another embodimentofthe invention, the thrombin
peptide derivative ofthe dimeris the polypeptide H-Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH, (SEQ ID NO:3). In
another specific embodiment, the thrombin peptide derivative
dimeris represented by the structural formula (IV).
In further embodiments, the NPAR agonist is an antibody
or antigen-binding fragmentthereof that binds to a comple-
mentary peptide, wherein the complementary peptide is
encoded by the complementofa nucleotide sequence encod-
ing a portion of thrombin.
The thrombin referred to above can be a mammalian
thrombin,and in particular, ahuman thrombin. The portion of
thrombin can be a thrombin receptor binding domain or a
portion thereof. In one embodiment, the thrombin receptor
binding domain orportion thereof comprises the amino acid
sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-
Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ
ID NO:6). Another portion of a thrombin receptor binding
domain comprises the amino acid sequence Glu-Gly-Lys-
Arg-Gly-Asp-Ala-Cys-Glu-Gly (SEQ ID NO:7).
The complementary peptide to which the antibody or the
antigen-binding fragment thereof binds can be encoded by
the 5'-3' sequenceofthe antisense RNA strand or encoded by
the 3'-5' sequence of the antisense RNA strand.
In specific embodiments, the complementary peptide com-
prises the amino acid sequence Lys-Gly-Ser-Pro-Thr-Val-
Thr-Phe-Thr-Gly-Ie-Pro-Cys-Phe-Pro-Phe-Ie-Arg-Leu-
Val-Thr-Ser (SEQ ID NO:8) or Thr-Phe-Thr-Gly-Ie-Pro-
Ser-Phe-Pro-Phe (SEQ ID NO:9) or Arg-Pro-Met-Phe-Gly-
Leu-Leu-Pro-Phe-Ala-Pro-Leu-Arg-Thr-Leu-Pro-Leu-Ser-
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Pro-Pro-Gly-Lys-Gln (SEQ ID NO:10) or Lys-Pro-Phe-Ala-
Pro-Leu-Arg-Thr-Leu-Pro (SEQ ID NO:11).
The NPARagonist to be used in the methodsofthe inven-
tion can be a polyclonal antibody, or a monoclonal antibody
or antigen-binding fragmentthereof. In particular embodi-
ments, these are human antibodies. Monoclonalantibodies to
be used as NPAR agonists in methods of therapy can be
humanized antibodies, chimeric antibodies or antigen-bind-
ing fragments ofany ofthe foregoing, which can include Fab
fragments, Fab' fragments, F(ab’), fragments and Fv frag-
ments.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows X-ray films from a representative western
blot and a corresponding bar graph ofratios of densitometry
readings from the bands on western blots from experiments
examining the effect of TP508 on expression levels of argin-
ase | in cells cultured with or without TNFa. Humancoro-
nary artery endothelial (HCAE) cells were incubated in the
absence (CTR) or presence of TP508 (TP) for 1 h prior to
treatment with TNFa for 24 h. Cell lysates were analyzed for
human arginase 1 expression by immunoblotting using anti-
body specific for this enzyme. After stripping, the membrane
wasreprobedwith GAPDHantibodyto show protein loading.
(Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)lev-
els are unaffected by TNFa or hypoxia.) Corresponding den-
sitometric data represent the meanzSD of 4 independent
experiments [p<0.05; CTR vs. TNFa (*) or TNFa vs.
TP+TNFa. (*)].
FIG. 2 shows X-ray films from western blot experiments
and a correspondingbargraphofratios ofdensitometry read-
ings from the bands on the western blot showing a dose-
response effect of TP508 on arginase 1 upregulation by
TNFa. HCAEcells were pretreated with TP508at the indi-
cated concentration for 1 h before stimulation with TNFa for
24h and cell lysates were analyzed for arginase 1 expression
by immunoblotting. Densitometric analysis showsrelative
intensities of arginase 1 expression.
FIG. 3 shows X-ray films from western blots and corre-
sponding bar graphsofratios of densitometry readings from
the bands on the western blots from experiments showing the
effect of TP508 on expression and phosphorylation (activa-
tion) of eNOS. HCAEcells were stimulated with TP508 or
TNFa and incubated in normoxic or 1% oxygen (hypoxic)
conditions for 24 h. Cell lysates were analyzed for eNOS
activation by immunoblotting using antibody specific for
eNOSphosphorylated at $1177. After stripping, the mem-
brane was reprobed with antibodies for total eNOS and
GAPDH. Corresponding densitometric data represent the
mean+SD of 3 independent experiments [* signifies p<0.05;
CTRvs. TP(*) (normoxia); CTR vs. TP(*) (hypoxia)].
FIG. 4 shows X-ray films from western blot experiments
and corresponding bar graphsofratios of densitometry read-
ings from the bands on the western blots from experiments
examining the dose dependenceof the effects of TP508 on
eNOSactivation. HCAEcells were treated with TP508at the
indicated concentrations for 24 h and analyzed for eNOS
activity and expression as in FIG. 3. Densitometric analysis
shows changes in eNOS phosphorylation relative to total
eNOSafter TP508 treatment.
FIG. 5 showsstained gels of products of RT-PCR from
experiments designed to investigate the effect of TP508 on
eNOS mRNA. Changes in eNOS mRNA expression in cells
stimulated with TNFa or TP508 for 6 h were analyzed using
RT-PCR.
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FIG.6 is a bar graph of data from quantitative analysis of
eNOS mRNAexpression. HCAEcells were stimulated with
TP508 or TNFa, and incubated in normoxic or hypoxic (1%
oxygen) conditions for 24 h. RNA was analyzed for eNOS
expression using SYBR Green real-time PCR. p<0.05 when
compared with absence of TP508 (CTR)for each condition.
FIG.7 depicts the encoded amino acid sequence ofhuman
pro-thrombin (SEQ ID NO: 12). Aminoacids 508-530, which
contain the thrombin receptor binding domain, are under-
lined. Thrombin consists of the C-terminal 579 amino acid
residues of prothrombin. See GenBank Accession No.
AJ972449,
FIG. 8 is a graph showing densitometric analysis of a
Western blot of activated endothelial nitric oxide synthase
(eNOS) in HCAEcells following treatments with TP508,
VEGFor a combination thereof.
FIG. 9A is a diagram showing the experimental apparatus
and design of experiments to measure migration of endothe-
lial cells toward a chemoattractant.
FIG.9Bis a bar graph showing the effect of TP508 treat-
ment on migration of endothelial cells toward the angiogenic
factor VEGF.
FIG. 10A is a diagram showingthe experimental apparatus
and design ofexperiments to measure invasion of endothelial
cells through Matrigel toward a chemoattractant.
FIG. 10B is a bar graph showing the effect of TP508
treatment on invasion of endothelial cells toward the angio-
genic factor VEGF.
FIG. 11 is a graph showing the increase inVEGF mRNAin
human cardiac microvascular endothelial cells treated with
VEGF or with TP508 under normal oxygen conditions or
hypoxic conditions.
FIG. 12 is a graph of data from measurements on rings of
rat aorta to assess the relaxanteffect of TP508.
FIGS. 13A-13D are graphs showingthe extent of dilation
of coronary arterioles from ischemic hearts under conditions
as shown. FIGS. 13A-13B show endothelium-dependent
NOmediated vasodilation. The degree of endothelial dys-
function was evaluated in arterioles isolated from normoxic
control left anterior descending artery (Nonischemic) or
ischemicleft circumflex coronary artery ofplacebo (Ischemic
placebo) or TP508-treated (Ischemic TP508) hearts by deter-
mining the degree ofvasodilation as a percentage ofmaximal
dilation in response to indicated concentrations of adenosine
(FIG. 13A)or serotonin (FIG. 13B). *p<0.05 compared with
nonischemic; #p<0.05 compared with ischemic placebo.
FIGS. 13C and 13D show endothelium-independent NO-
mediated vasodilation. To determine potential effects of
ischemia and TP508 on NO-independent vasodilation, iso-
lated arterioles were stimulated with the indicated concentra-
tions of nitroprusside (FIG. 13C)or pinacidil (FIG. 13D).
FIG. 13E is a bar graph showingresults of treating arteri-
oles isolated from nonischemic and ischemic hearts with
either placebo or TP508, and analyzing for NO production.
DETAILED DESCRIPTION OF THE INVENTION
Endothelial dysfunction has been implicated in the etiol-
ogy of a variety of diseases including hypertension, conges-
tive heart failure, coronary artery disease, stroke, cerebrovas-
cular disease, peripheral vascular disease, diabetes, erectile
dysfunction, atherosclerosis, asthma, rheumatoid arthritis,
pulmonary hypertension, acute lung injury, chronic obstruc-
tive pulmonary disease (COPD), cystic fibrosis, inflamma-
tory lung disease, hyperhomocysteinemia,sickle cell disease,
pre-eclampsia, chronic renal failure, chronic renal dysfunc-
tion, renal microvascular disease, hepatic reperfusion injury,
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neuropathy, Alzheimer’s disease, thyroid disease, sepsis,
thrombosis, multiple organ failure, inflammatory bowel dis-
ease, and radiation damage.
Applicants have discovered that compounds which stimu-
late or activate the non-proteolytically activated thrombin
receptor (hereinafter “NPAR”) can reverse or inhibit endot-
helial dysfunction by blocking the up-regulation of arginase
associated with endothelial dysfunction and by promoting the
activation or up-regulation of nitric oxide synthase, thereby
increasing the production of nitric oxide. TP508 blocks the
up-regulation of arginase induced by TNFa. The effect is
dose dependent. TP508 treatment also increases phosphory-
lation of eNOS in cells cultured under normoxic (normal
oxygen) and hypoxic (1% oxygen) conditions. Moreover,
TP508 stimulation of cells prevents hypoxia-induced down-
regulation of eNOSexpression, to maintain eNOSat a level
that remains close to what wouldbe observedin cells cultured
under normoxic conditions. The effects of TP508 on eNOS
phosphorylation are dose dependent (Example 3).
The invention includes methods of treating endothelial
dysfunction, and methods of treating the consequences of
endothelial dysfunction, at a site in a subject in need thereof,
comprising administering to the subject a therapeutically
effective amountofan agonistofthe non-proteolytically acti-
vated thrombin receptor, wherein the site is not an artery
injured by angioplasty, a chronic skin ulcer, a site in need of
osteoinduction ora site in need of cardiac revascularization.
In particular embodiments, the subject to be treated is suffer-
ing from or has suffered from one or more disease(s) selected
from the group consisting of hypertension, congestive heart
failure, coronary artery disease, stroke, cerebrovascular dis-
ease, peripheral vascular disease, diabetes, erectile dysfunc-
tion, atherosclerosis, asthma, rheumatoid arthritis, pulmo-
nary hypertension, acute lung injury, chronic obstructive
pulmonary disease (COPD), cystic fibrosis, inflammatory
lung disease, hyperhomocysteinemia, sickle cell disease, pre-
eclampsia, chronic renal failure, chronic renal dysfunction,
renal microvascular disease, hepatic reperfusion injury, neu-
ropathy, Alzheimer’s disease, thyroid disease, sepsis, throm-
bosis, multiple organ failure, inflammatory bowel disease,
and radiation damage.
In a particular aspect, the invention is a methodoftreating
endothelial dysfunction, thereby treating impaired glucose
tolerance ina subject, comprising administering to the subject
a therapeutically effective amount of an agonist of the non-
proteolytically activated thrombin receptor. Subjects with
impaired glucose intolerance include thoseat risk of devel-
oping type 2 diabetes. In another aspect, the invention is a
methodof treating endothelial dysfunction, thereby treating
the complicationsofdiabetes in a subject, comprising admin-
istering to the subject a therapeutically effective amount ofan
agonist of the non-proteolytically activated thrombin recep-
tor. In these aspects, the subject is not in need oftreatmentat
a site which is an artery injured by angioplasty, a chronic skin
ulcer, a site in need of osteoinduction or a site in need of
cardiac revascularization.
In another aspect, the invention is a method oftreating
atherosclerosis in a subject, comprising administering to the
subject a therapeutically effective amountofan agonist ofthe
non-proteolytically activated thrombin receptor. In this
aspect, the subject is not in need of treatmentat a site which
is an artery injured by angioplasty, a chronic skin ulcer, a site
in need of osteoinduction or a site in need of cardiac revas-
cularization.
Endothelial dysfunction is a cause oftoxicity from ionizing
radiation. In the irradiated gut, for example, endothelial cells
are depleted, leading to breakdown of the mucosalbarrier,
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which,in turn, leads to inflammation, the production of reac-
tive oxygen species, and the release of signaling molecules
such as TGF-B and TNF-a. Amongthe effects ofthis inflam-
matory reaction are a decrease in crypt cell proliferation,
mucositis and secretory diarrhea, and increases in mesenchy-
mal cell proliferation and collagen production, leading to
fibrosis and scarring. A subject can suffer damage from ion-
izing radiation following high doses of therapeutic radiation
as treatment for various forms of cancer, or in case of radia-
tion exposure from an industrial accident, for example.
In still another aspect, the invention is a methodoftreating
radiation damage in a subject, comprising administering to
the subject a therapeutically effective amount ofan agonist of
the non-proteolytically activated thrombin receptor. In this
aspect, the subject is not in need of treatmentat a site which
is an artery injured by angioplasty, a chronic skin ulcer, a site
in need of osteoinduction or a site in need of cardiac revas-
cularization.
NPARAgonists
Compounds which stimulate NPARare said to be NPAR
agonists. NPARis a high-affinity thrombin receptor present
on the surface ofmost cells. This NPAR componentis largely
responsible for high-affinity binding of thrombin,proteolyti-
cally inactivated thrombin, and thrombin derived peptides to
cells. NPAR appears to mediate a numberofcellular signals
that are initiated by thrombin independentof its proteolytic
activity. An example ofone such signalis the upregulation of
annexin V and other molecules identified by subtractive
hybridization (see Sower,et. al., Experimental Cell Research
247:422 (1999)). NPARis therefore characterized by its high
affinity interaction with thrombinat cell surfaces andits acti-
vation by proteolytically inactive derivatives ofthrombin and
thrombin derived peptide agonists as described below. NPAR
activation can be assayed basedontheability ofmolecules to
stimulate cell proliferation when addedto fibroblasts in the
presence of submitogenic concentrations ofthrombin or mol-
ecules that activate protein kinase C, as disclosed in US.Pat.
Nos. 5,352,664 and 5,500,412. The entire teachings of these
patents are incorporated herein by reference. NPAR agonists
can be identified by this activation orby their ability to com-
pete with ‘*°I-thrombin bindingto cells.
A thrombin receptor binding domain is defined as a
polypeptide or portion of a polypeptide which directly binds
to the thrombin receptor and/or competitively inhibits bind-
ing between high-affinity thrombin receptors and alpha-
thrombin.
NPARagonists of the present invention include thrombin
derivative peptides, modified thrombin derivative peptides,
thrombin derivative peptide dimers and NPAR agonist anti-
bodies to complementary peptides of thrombin as disclosed
herein.
Thrombin Derivative Peptides
Among NPARagonists are thrombin peptide derivatives
(also: “thrombin derivative peptides”), which are analogs of
thrombin that have an amino acid sequencederivedat least in
part from that of thrombin andare active at the non-pro-
teolytically activated thrombin receptor. Thrombin peptide
derivatives include, for example, peptides that are produced
by recombinant DNA methods, peptides produced by enzy-
matic digestion ofthrombin, and peptides produced syntheti-
cally, which can comprise amino acid substitutions compared
to thrombin and/or modified amino acids, especially at the
termini.
NPARagonists of the present invention include thrombin
derivative peptides described in U.S. Pat. Nos. 5,352,664 and
5,500,412. In one embodiment, the NPAR agonist of the
present invention is a thrombin peptide derivative or a physi-
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ologically functional equivalent, i.e., a polypeptide with no
more than aboutfifty amino acids, preferably no more than
about thirty amino acids and having sufficient homology to
the fragment of human thrombin corresponding to thrombin
amino acids 508-530 (Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val; SEQ ID NO:6) that the polypeptide activates NPAR.
The thrombin peptide derivatives or modified thrombin pep-
tide derivatives described herein preferably have from about
12 to about 23 amino acid residues, more preferably from
about 19 to about 23 aminoacid residues.
In another embodiment, the NPAR agonist of the present
invention is a thrombin peptide derivative comprising a moi-
ety represented by Structural Formula (1):
Asp-Ala-R (1).
R is a serine esterase conserved domain. Serine esterases,
e.g., trypsin, thrombin, chymotrypsin and the like, have a
region that is highly conserved. “Serine esterase conserved
domain” refers to a polypeptide having the amino acid
sequence of one of these conserved regionsoris sufficiently
homologous to one of these conserved regions such that the
thrombin peptide derivative retains NPARactivating ability.
A physiologically functional equivalent of a thrombin
derivative encompasses molecules which differ from throm-
bin derivatives in particulars which do not affect the function
of the thrombin receptor binding domain or the serine
esterase conserved amino acid sequence. Such particulars
may include, but are not limited to, conservative amino acid
substitutions (as definedbelow for NPARagonists) and modi-
fications, for example, amidation of the carboxyl terminus,
acetylation of the amino terminus, conjugation of the
polypeptide to a physiologically inert carrier molecule, or
sequence alterations in accordance with the serine esterase
conserved sequences.
A domain having aserine esterase conserved sequence can
comprise a polypeptide sequence containing at least 4-12 of
the N-terminal amino acids of the dodecapeptide previously
shownto be highly conserved amongserine proteases (Asp-
X,-Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val; SEQ ID
NO:13); wherein X, is either Ala or Ser; X, is either Glu or
Gln; and X, is Phe, Met, Leu, His, or Val).
In one embodiment, the serine esterase conserved
sequence comprises the amino acid sequence of SEQ ID
NO:14 (Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) or a
C-terminal truncated fragment of a polypeptide having the
amino acid sequence of SEQ ID NO:14. It is understood,
however, that zero, one, two or three amino acidsin the serine
esterase conserved sequence can differ from the correspond-
ing amino acid in SEQ ID NO:14. Preferably, the amino acids
in the serine esterase conserved sequence which differ from
the corresponding amino acid in SEQ ID NO:14 are conser-
vative substitutions as defined below, and are more preferably
highly conservative substitutions. A “C-terminal truncated
fragment”refers to a fragment remaining after removing an
amino acid or block ofaminoacids from the C-terminus, said
fragmenthaving at least six and more preferably at least nine
aminoacids.
In another embodiment, the serine esterase conserved
sequence comprises the amino acid sequence of SEQ ID
NO:15 (Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val; X, is
Glu or Gln and X, is Phe, Met, Leu, His orVal) ora C-terminal
truncated fragment thereof having at least six amino acids,
preferably at least nine amino acids.
Ina preferred embodiment, the thrombin peptide derivative
comprises a serine esterase conserved sequence and a
polypeptide having a more specific thrombin amino acid
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sequence Arg-Gly-Asp-Ala (SEQ ID NO:16). One example
of a thrombin peptide derivative of this type comprises Arg-
Gly-Asp-Ala-Cys-X , -Gly-Asp-Ser-Gly-Gly-Pro-X,-Val
(SEQ ID NO:1). X, and X, are as defined above. The throm-
bin peptide derivative can comprise the amino acid sequence
of SEQ ID NO:6 (Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-
Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-
Val) or an N-terminal truncated fragment thereof, provided
that zero, one, two or three aminoacidsat positions 1-9 in the
thrombin peptide derivative differ from the amino acid at the
corresponding position of SEQ ID NO:6. Preferably, the
aminoacid residues in the thrombin peptide derivative which
differ from the corresponding aminoacid residues in SEQ ID
NO:6 are conservative substitutions as defined below for
NPARagonists, and are more preferably highly conservative
substitutions. An “N-terminaltruncated fragment”refers to a
fragment remaining after removing an aminoacid or block of
amino acids from the N-terminus, preferably a block of no
more than six amino acids, more preferably a block of no
more than three amino acids.
Optionally, the thrombin peptide derivatives described
herein can be amidated at the C-terminus and/or acylated at
the N-terminus. In a specific embodiment, the thrombin pep-
tide derivatives comprise a C-terminal amide and optionally
comprise an acylated N-terminus, wherein said C-terminal
amide is represented by —C(O)NR,R,, wherein R, and R,
are independently hydrogen, a C,-C,, substituted or unsub-
stituted aliphatic group, or R, and R,, taken together with the
nitrogen to which they are bonded, form a C,-C,, non-aro-
matic heterocyclic group, and said N-terminal acyl group is
represented by R.C(O)—, wherein R, is hydrogen, a C,-C,,
substituted or unsubstituted aliphatic group, or a C,-C,, sub-
stituted or unsubstituted aromatic group. In another specific
embodiment, the N-terminusofthe thrombin peptide deriva-
tive is free (i.e., unsubstituted) and the C-terminusisfree(1.e.,
unsubstituted) or amidated, preferably as a carboxamide(1.e.,
—C(O)NH.,). Ina specific embodiment, the thrombin peptide
derivative comprises the following amino acid sequence: Ala-
Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-
Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:6). In
another specific embodiment, the thrombin peptide derivative
comprises the amino sequence of Arg-Gly-Asp-Ala-Cys-
Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:17).
Alternatively, the thrombin peptide derivative comprises the
amino acid sequence of SEQ ID NO:18: Asp-Asn-Met-Phe-
Cys-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-
Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-
Ser-Pro-Phe. The thrombin peptide derivates comprising the
amino acids of SEQ ID NO:6, 17, or 18 can optionally be
amidated at the C-terminus and/or acylated at the N-terminus.
Preferably, the N-terminusisfree (i.e., unsubstituted) and the
C-terminus is free (1.e., unsubstituted) or amidated, prefer-
ably a carboxamide (i.e., —C(O)NH,).It is understood, how-
ever, that zero, one, two or three aminoacids at positions 1-9
and 14-23 in the thrombin peptide derivative can differ from
the corresponding amino acid in SEQ ID NO:6.It is also
understood that zero, one, two or three amino acids at posi-
tions 1-14 and 19-33 in the thrombin peptide derivative can
differ from the corresponding amino acid in SEQ ID NO:18.
Preferably, the aminoacids in the thrombin peptide derivative
which differ from the corresponding amino acid in SEQ ID
NO:6 or SEQ ID NO:18 are conservative substitutions as
defined below, and are more preferably highly conservative
substitutions. Alternatively, an N-terminal truncated frag-
mentofthe thrombin peptide derivative having at least four-
teen amino acids or a C-terminal truncated fragment of the
20
25
40
45
10
thrombin peptide derivative having at least eighteen amino
acidsis a thrombin peptide derivative to be used as an NPAR
agonist.
A “C-terminal truncated fragment” refers to a fragment
remaining after removing an aminoacid or block of amino
acids from the C-terminus. An “N-terminal truncated frag-
ment” refers to a fragment remaining after removing an
aminoacid or block ofamino acids from the N-terminus.It is
to be understood that the terms “C-terminal truncated frag-
ment” and “N-terminal truncated fragment” encompass acy-
lation at the N-terminus and/or amidation at the C-terminus,
as described above.
A preferred thrombin peptide derivative for use in the dis-
closed method comprises the amino acid sequence SEQ ID
NO:2: —Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-
Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val.
Anotherpreferred thrombin peptide derivative for use in the
disclosed method comprises the amino acid sequence ofSEQ
ID NO:19: Asp-Asn-Met-Phe-Cys-Ala-Gly-Tyr-Lys-Pro-
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-
Gly-Gly-Pro-X,-Val-Met-Lys-Ser-Pro-Phe. X, is Glu or Gln;
X, is Phe, Met, Leu, His or Val. The thrombin peptide deriva-
tives of SEQ ID NO:2 and SEQ ID NO:19 can optionally
comprise a C-terminal amide and/or acylated N-terminus, as
defined above. Preferably, the N-terminusisfree (i.e., unsub-
stituted) and the C-terminusis free (i.e., unsubstituted) or
amidated, preferably as a carboxamide (i.e., —C(O)NH,).
Alternatively, N-terminal truncated fragments of these pre-
ferred thrombin peptide derivatives, the N-terminal truncated
fragments having at least fourteen amino acids, or C-terminal
truncated fragments of these preferred thrombin peptide
derivatives, the C-terminal truncated fragments having at
least eighteen amino acids, can also be used in the disclosed
method.
TP508 is an example of a thrombin peptide derivative and
is 23 aminoacid residues long, wherein the N-terminal amino
acid residue Ala is unsubstituted and the COOHofthe C-ter-
minal amino acid Val is modified to an amide represented by
—C(O)NH, (SEQ ID NO:3). Another example ofa thrombin
peptide derivative comprises the amino acid sequence ofSEQ
ID NO:6, wherein both N- and C-termini are unsubstituted
(“deamide TP508”). Other examples of thrombin peptide
derivatives which can be used in the disclosed method include
N-terminal truncated fragments of TP508 (or deamide
TP508), the N-terminal truncated fragments having at least
fourteen amino acids, or C-terminal truncated fragments of
TP508 (or deamide TP508), the C-terminal truncated frag-
ments having at least eighteen amino acids.
Asusedherein,a “conservative substitution”in a polypep-
tide is the replacement of an amino acid with another amino
acid that has the same net electronic charge and approxi-
mately the samesize and shape. Aminoacids with aliphatic or
substituted aliphatic amino acid side chains have approxi-
mately the same size when the total number of carbon and
heteroatomsin their side chains differs by no more than about
four. They have approximately the same shape when the
numberof branches in their side chains differs by no more
than one. Amino acids with phenyl or substituted phenyl
groups in their side chains are considered to have about the
same size and shape. Listed below are five groups of amino
acids. Replacing an aminoacid in a polypeptide with another
amino acid from the same group results in a conservative
substitution:
Group I: glycine, alanine, valine, leucine, isoleucine,
serine, threonine, cysteine, and non-naturally occurring
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amino acids with C1-C4 aliphatic or C1-C4 hydroxyl
substituted aliphatic side chains (straight chained or
monobranched).
Group II: glutamic acid, aspartic acid and non-naturally
occurring amino acids with carboxylic acid substituted
C1-C4 aliphatic side chains (unbranchedor one branch
point).
Group III: lysine, ornithine, arginine and non-naturally
occurring amino acids with amine or guanidino substi-
tuted C1-C4 aliphatic side chains (unbranched or one
branch point).
Group IV: glutamine, asparagine and non-naturally occur-
ring amino acids with amidesubstituted C1-C4aliphatic
side chains (unbranchedor one branch point).
Group V: phenylalanine, phenylglycine, tyrosine andtryp-
tophan.
Asused herein, a “highly conservative substitution” in a
polypeptide is the replacement ofan amino acid with another
amino acid that has the same functional group in the side
chain and nearly the same size and shape. Amino acids with
aliphatic or substituted aliphatic amino acid side chains have
nearly the same size when the total number of carbon and
heteroatomsin their side chains differs by no more than two.
They have nearly the same shape when they have the same
number of branches in the their side chains. Examples of
highly conservative substitutions include valine for leucine,
threonine for serine, aspartic acid for glutamic acid and phe-
nylglycine for phenylalanine. Examples of substitutions
whichare not highly conservative include alaninefor valine,
alanine for serine and aspartic acid for serine.
Modified Thrombin Peptide Derivatives
Tn one embodimentofthe invention, the NPARagonists are
modified relative to the thrombin peptide derivatives
described above, wherein cysteine residues of aforemen-
tioned thrombin peptide derivatives are replaced with amino
acids having similar size and charge properties to minimize
dimerization of the peptides. Examples of suitable amino
acids include alanine, glycine, serine, or an S-protected cys-
teine. Preferably, cysteine is replaced with alanine. The modi-
fied thrombin peptide derivatives have about the same bio-
logical activity as the unmodified thrombin peptide
derivatives. See Publication No. US 2005/0158301 Al, which
is hereby incorporated by reference.
Tt will be understood that the modified thrombin peptide
derivatives disclosed herein can optionally comprise C-ter-
minal amides and/or N-terminal acyl groups, as described
above. Preferably, the N-terminus of a thrombin peptide
derivative is free (i.e., unsubstituted) and the C-terminusis
free (i.e., unsubstituted) or amidated, preferably as a carboxa-
mide (i.e., —C(O)NH,).
In a specific embodiment, the modified thrombin peptide
derivative comprises a polypeptide having the amino acid
sequence of SEQ ID NO:4: Arg-Gly-Asp-Ala-Xaa-X,-Gly-
Asp-Ser-Gly-Gly-Pro-X,-Val, or a C-terminal truncated
fragment thereof having at least six amino acids. More spe-
cifically, the thrombin peptide derivative comprises the amino
acid sequence of SEQ ID NO:20: Ala-Gly-Tyr-Lys-Pro-Asp-
Glu-Gly-Lys-Arg-Gly-Asp-Ala-Xaa-Glu-Gly-Asp-Ser-Gly-
Gly-Pro-Phe-Val or a fragment thereof comprising amino
acids 10-18 of SEQ ID NO:20. Even more specifically, the
thrombin peptide derivative comprises the amino acid
sequence SEQ ID NO:5: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-
Gly-Lys-Arg-Gly-Asp-Ala-Xaa-X,-Gly-Asp-Ser-Gly-Gly-
Pro-X,-Val, or a fragment thereof comprising amino acids
10-18 of SEQ ID NO:5. Xaais alanine, glycine, serine or an
S-protected cysteine. X, is Glu or Gln and X, is Phe, Met,
Leu, His or Val. Preferably X, is Glu, X, is Phe, and Xaa is
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alanine. One example of a thrombin peptide derivative ofthis
type is a polypeptide having the amino acid sequence Ala-
Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Ala-
Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:21). A
further example of a thrombin peptide derivative of this type
is the polypeptide H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Ala-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val-NH, (SEQ ID NO:22). Zero, one, two or three amino
acids in the thrombin peptide derivativediffer from the amino
acid at the correspondingposition of SEQ ID NO:4, 20, 5, 21
or 22, provided that Xaa is alanine, glycine, serine or an
S-protected cysteine. Preferably, the difference is conserva-
tive as defined for conservative substitutions of NPAR ago-
nists.
In another specific embodiment, the thrombin peptide
derivative comprises a polypeptide having the amino acid
sequence SEQ ID NO:23: Asp-Asn-Met-Phe-Xbb-Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Xaa-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-Ser-Pro-Phe,
or a fragment thereof comprising amino acids 6-28. More
preferably, the thrombin peptide derivative comprises a
polypeptide having the amino acid sequence SEQ ID NO:24:
Asp-Asn-Met-Phe-Xbb-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-
Gly-Lys-Arg-Gly-Asp-Ala-Xaa-X,-Gly-Asp-Ser-Gly-Gly-
Pro-X,-Val-Met-Lys-Ser-Pro-Phe, or a fragment thereof
comprising amino acids 6-28. Xaa and Xbbare independently
alanine, glycine, serine or an S-protected cysteine. X, is Glu
or Gln and X, is Phe, Met, Leu, His or Val. Preferably X, is
Glu, X, is Phe, and Xaa and Xbbare alanine. One example of
a thrombin peptide derivative of this type is a polypeptide
comprising the amino acid sequence Asp-Asn-Met-Phe-Ala-
Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-
Ala-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-Ser-
Pro-Phe (SEQ ID NO:25). A further example of a thrombin
peptide derivative ofthis type is the polypeptide H-Asp-Asn-
Met-Phe-Ala-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-
Gly-Asp-Ala-Ala-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-
Met-Lys-Ser-Pro-Phe-NH, (SEQ ID NO:26). Zero, one, two
or three amino acids in the thrombin peptide derivative can
differ from the amino acid at the corresponding position of
SEQ ID NO:23,24, 25 or 26. Xaa and Xbb are independently
alanine, glycine, serine or an S-protected cysteine. Prefer-
ably, the difference is conservative as in conservative substi-
tutions of NPARagonists.
An “S-protected cysteine” is a cysteine residue in which
the reactivity of the thiol moiety, —SH, is blocked with a
protecting group. Suitable protecting groups are knownin the
art and are disclosed, for example, in T. W. Greene and P. G.
M.Wuts, Protective Groups in Organic Synthesis, 3”¢ Edi-
tion, John Wiley & Sons, (1999), pp. 454-493, the teachings
ofwhichare incorporated herein by referencein their entirety.
Suitable protecting groups should be non-toxic, stable in
pharmaceutical formulations and have minimum additional
functionality to maintain the activity of the thrombin peptide
derivative. A free thiol can be protected as a thioether, a
thioester, or can be oxidized to an unsymmetrical disulfide.
Preferably the thiol is protected as a thioether. Suitable thio-
ethers include, but are not limited to, S-alkyl thioethers(e.g.,
C,-C, alkyl), and S-benzy] thioethers (e.g., cysteine-S—S-t-
Bu). Preferably the protective group is an alkyl thioether.
Morepreferably, the S-protected cysteine is an S-methyl cys-
teine. Alternatively, the protecting group can be: 1) a cysteine
or a cysteine-containing peptide (the “protecting peptide”)
attached to the cysteine thiol group of the thrombin peptide
derivative by a disulfide bond; or 2) an amino acid or peptide
(“protecting peptide”) attached by a thioamide bond between
the cysteine thiol group of the thrombin peptide derivative
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and a carboxylic acid in the protecting peptide (e.g., at the
C-terminus or side chain of aspartic acid or glutamic acid).
The protecting peptide can be physiologically inert (e.g., a
polyglycine or polyalanine ofno more than aboutfifty amino
acids optionally interrupted by a cysteine), or can have a
desirable biological activity.
Thrombin Peptide Derivative Dimers
In some aspects of the present invention, the NPAR ago-
nists of the methods are thrombin peptide derivative dimers.
See Publication No. US 2005/0153893, which is hereby
incorporated by reference. The dimers essentially do not
revert to monomersandstill have about the same biological
activity as the thrombin peptide derivatives monomer
described above. A “thrombin peptide derivative dimer” is a
molecule comprising two thrombin peptide derivatives linked
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Phe. One example of a thrombin peptide derivative of this
type is a polypeptide comprising the amino acid sequence
Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-
Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID
NO:6). A further example of a thrombin peptide derivative of
this type is a polypeptide having the amino acid sequence
H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-
Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH, (SEQ
ID NO:3). Zero, one, two or three amino acids in the thrombin
peptide derivative differ from the amino acid at the corre-
sponding position of SEQ ID NO:6,1, 2, or 3. Preferably, the
difference is conservative as for conservative substitutions of
NPARagonists.
One example of a thrombin peptide derivative dimer ofthe
present invention is represented by Formula (IV):
qv)
HH-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-N
N-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NHH
HN-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH>
H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-NH
by a covalent bond, preferably a disulfide bond between cys-
teine residues. Thrombin peptide derivative dimers are typi-
cally essentially free of the corresponding monomer, e.g.,
greater than 95% free by weight and preferably greater than
99% free by weight. Preferably the polypeptides are the same
and covalently linked through a disulfide bond.
The thrombin peptide derivative dimers of the present
invention comprises the thrombin peptide derivatives
described above. Specifically, thrombin peptide derivatives
have less than about fifty amino acids, preferably less than
aboutthirty-three amino acids. Thrombin peptide derivatives
also have sufficient homology to the fragment of human
thrombin corresponding to thrombin amino acid residues
508-530: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-
Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ
ID NO:6)so that the polypeptide activates NPAR. The throm-
bin peptide derivative dimers described herein are formed
from polypeptides typically having at least six amino acids
and preferably from about 12 to about 33 amino acid residues,
and more preferably from about 12 to about 23 amino acid
residues.
Ina specific embodiment, eachthrombin peptidederivative
comprising a dimer comprises a polypeptide having the
amino acid sequence SEQ ID NO:1: Arg-Gly-Asp-Ala-Cys-
X_,-Gly-Asp-Ser-Gly-Gly-Pro-X,-Val, or a C-terminal trun-
cated fragment thereof comprising at least six amino acids.
Morespecifically, each thrombin peptide derivative com-
prises the amino acid sequence of SEQ ID NO:6: Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, or a fragment thereof
comprising amino acids 10-18 of SEQ ID NO. 5. Even more
specifically, the thrombin peptide derivative comprises the
amino acid sequence SEQ ID NO:2: Ala-Gly-Tyr-Lys-Pro-
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X , -Gly-Asp-Ser-
Gly-Gly-Pro-X,-Val, or a fragment thereof comprising
amino acids 10-18 of SEQ ID NO:2. X, is Glu or Gln and X,
is Phe, Met, Leu, His or Val. Preferably X, is Glu, and X, is
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In another specific embodiment, each thrombin peptide
derivative comprising a dimer comprises a polypeptide com-
prising the amino acid sequence SEQ ID NO:27: Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-Ser-Pro-Phe-
Asn-Asn-Arg-Trp-Tyr, or a C-terminal truncated fragment
thereof having at least twenty-three amino acids. Morepref-
erably, each thrombin peptide derivative comprises the amino
acid sequence SEQ ID NO:28: Ala-Gly-Tyr-Lys-Pro-Asp-
Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X , -Gly-Asp-Ser-Gly-
Gly-Pro-X.,-Val-Met-Lys-Ser-Pro-Phe-Asn-Asn-Arg-Trp-
Tyr, or a C-terminaltruncated fragment thereofcomprising at
least twenty-three amino acids. X, is Glu orGIn and X,is Phe,
Met, Leu, HisorVal. Preferably X, is Glu, and X, is Phe. One
example of a thrombin peptide derivative of this type is a
polypeptide comprising the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-
Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-Ser-Pro-Phe-
Asn-Asn-Arg-Trp-Tyr (SEQ ID NO:27). A further example
of a thrombin peptide derivative of this type is a polypeptide
comprising the amino acid sequence H-Ala-Gly-Tyr-Lys-
Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-
Asp-Ser-Gly-Gly-Pro-Phe-Val-Met-Lys-Ser-Pro-Phe-Asn-
Asn-Arg-Trp-Tyr-NH, (SEQ ID NO:29). Zero, one, two or
three amino acids in the thrombin peptide derivative differ
from the aminoacid at the corresponding position of SEQ ID
NO:27, 28 or 29. Preferably, the difference is conservative as
defined for conservative substitutions ofNPAR agonists.
NPARAgonist Antibodies
A particular class of NPAR agonists includes antibodies
and antigen-binding fragments that can both bind to and
activate the non-proteolytically activated thrombin receptor
(NPAR), and can bind to one or more complementary pep-
tides as described below. Agonist antibodies that bind to
thrombin receptors have been described in the art. For
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example, Frostet al. teach that a monoclonal antibody, TR-9,
can mimic the effects of thrombin’s high affinity interaction
with the high affinity thrombin receptor (Frost, G. H., et al., J.
Cell Biol. 105 (6 PT. 1):2551-58 (1987)).
Antibodies or antigen-binding fragments thereof that are
NPARagonists can be found by their binding to a comple-
mentary peptide that is encoded by the complement of a
nucleotide sequence encoding a portion of thrombin. See
Molecular Recognition Theory below. In one instance, the
NPARagonist antibody or antigen-binding fragmentbinds to
a complementary peptide that is encoded by the complement
of a nucleotide sequence encoding a portion of thrombin. In
another instance, the NPARagonist antibodyor antigen-bind-
ing fragment can be foundbyits binding to a complementary
peptide that is encoded by the complementof a nucleotide
sequence encoding a portion of thrombin. In one embodi-
ment, the thrombin or portion thereof (which is encoded by
the sense or +RNA strand andis the complement ofthe RNA
strand encoding the complementary peptide to which the
antibody or antigen-binding fragment binds) is a mammalian
thrombin or a portion of a mammalian thrombin. In another
embodiment, the thrombin or portion thereof is a human
thrombin or a portion of a human thrombin.
Antibodies or antigen-binding fragments thereof that bind
to a complementary peptide, wherein the complementary
peptide is encoded by the complement of a nucleotide
sequence encoding thrombin or a portion thereof, can be
NPARagonists. In one embodiment, the portion ofthrombin
(which is encoded by the sense or +RNAstrand andis the
complementofthe RNA strand encoding the complementary
peptide to which the antibody or antigen-binding fragment
binds) is a thrombin receptor binding domain or a portion
thereof. As used herein, a thrombin receptor binding domain
or a portion thereofis a segment ofthrombinthat is capable of
selectively binding to the high-affinity non-proteolytically
activated thrombin receptor (NPAR). Such thrombin receptor
binding domains contain a portion of a domain (represented
by amino acid residues 517-520 ofhuman thrombin;see FIG.
7 depicting the amino acid sequence of human prothrombin
(SEQ ID NO:12) with a sequence homologoustothe tripep-
tide cell binding domain of fibronectin, Arg-Gly-Asp. In a
particular embodiment, the thrombin receptor binding
domainorportion thereofcomprises the amino acid sequence
AGYKPDEGKRGDACEGDSGGPFV (i.e., amino acids
508-530 of human thrombin (SEQ ID NO:6)). In another
embodiment, the thrombin receptor binding domain or por-
tion thereof is a portion of the thrombin receptor binding
domain and comprises the amino acid sequence EGKRG-
DACEG(SEQ ID NO:7).
Asdescribed herein, complementary peptides of domains
ofthrombin that are encoded by both the 5'-3' sequenceofthe
antisense RNAstrand andthe 3'-5' sequence ofthe antisense
RNAstrand can be used to produce the NPAR agonist anti-
bodies and antigen-binding domainsofthe invention. There-
fore, in one embodiment, the complementary peptide (to
which the antibodies and antigen-binding fragments bind)is
encodedbythe 5'-3' sequence ofthe antisense RNAstrand. In
another embodiment, the complementary peptide is encoded
by the 3'-5' sequence of the antisense RNAstrand.
In one example, a complementary peptide (to which the
NPARagonist antibodies and antigen-binding fragments of
the invention bind) comprises the amino acid sequence
KGSPTVTFTGIPCFPFIRLVTS (AC-23; SEQ ID NO:30).
In another example, the complementary peptide comprises
the amino acid sequence KGSPTVTFTGIPSFPFIRLVTS
(23C53; SEQ ID NO:31). In yet another example, the
complementary peptide comprises the amino acid sequence
10
15
20
25
30
35
40
45
50
55
60
65
16
TFTGIPSFPF (C1053; SEQ ID NO:32). In still another
example, the complementary peptide comprises the amino
acid sequence RPMFGLLPFAPLRTLPLSPPGKQ [AC-
23rev (SEQ ID NO:33), which is the complementary 5'-3'
peptide corresponding to AC-23]. In still a further example,
the complementary peptide comprises the amino acid
sequence LPFAPLRTLP [C1053rev (SEQ ID NO:34), which
is the complementary 5'-3' peptide corresponding to C1053].
One example of an NPAR agonist antibody or an antigen-
binding fragment thereofbindsto a cysteine-altering comple-
mentary peptide comprising the amino acid sequence
KGSPTVTFTGIPSFPFIRLVTS (23C53; SEQ ID NO:31).
23C53, which differs from AC-23 by a single amino acid,is
the complementary peptide ofTP508, except that it possesses
a single aminoacid alteration from Cysto Ser.
In binding experiments using biotin-conjugated thrombin,
thrombin was found to bind specifically to AC23 and 23C53.
Half maximal binding of biotin-labeled thrombin to AC-23
was 4.840.2 nM (n=24SD).
Addition of TP508 inhibited specific binding of biotin-
labeled thrombin to AC-23. Up to 60% of the binding of
thrombin to AC-23 can be inhibited by the addition ofTP508.
Therefore, both thrombin and TP508 bind to the complemen-
tary peptide, AC-23. This suggests that AC-23 has a three-
dimensionalstructure that is similar to the thrombin-TP508
receptor on cells. Antibodies to AC-23 and other complemen-
tary peptides ofthrombin can therefore be used to character-
ize the thrombin bindingsite that is activated by TP508, and
can be used in the therapeutic and other methods described
herein.
In addition to the thrombin receptor binding domain, the
stimulatory (agonistic) thrombin polypeptide derivatives pos-
sess a domain (representedby aminoacid residues 519-530 of
human thrombin) with a high degree of homologyto a num-
ber of serine esterases. However, the inhibitory (antagonistic)
thrombin polypeptide derivatives do not include the serine
esterase domain.
Thrombin peptide derivatives from amino acid residues
508-530 ofhuman thrombin have been described for promot-
ing thrombin receptor mediated cell stimulation.In addition,
stimulatory (agonistic) thrombin polypeptide derivatives
containing both fibronectin- and serine protease-homologous
domains (residues 508 to 530 of human thrombin) bind to
thrombin receptors with high-affinity and substitute for DIP-
alpha-thrombin as an initiator of receptor occupancy-related
mitogenic signals. (DIP-alpha-thrombin is a proteolytically
inactive derivative of thrombin that retains receptor binding
activity.) In contrast, inhibitory (antagonistic) thrombin
polypeptide derivatives containing only the fibronectin-ho-
mologous domain (p517-520) (but not the serine protease-
homologous domain) bind to the thrombin receptor without
inducing mitogenesis. An intermediate thrombin peptide
derivative (p519-530) retains the ability to mediate mitogen-
esis but to a muchlesser degree than p508-530.
Molecular Recognition Theory
Blalock and Smith (1984) observed that the hydropathic
character ofan aminoacid residueis related to the identity of
the middle letter of the triplet codon from which it is tran-
scribed (Blalock, J. E., and Smith, E. M., Biochem. Biophys.
Res. Commun. 12: 203-07 (1984)). Specifically, a triplet
codon with thymine (T) as its middle base codesfor a hydro-
phobic residue while adenine (A) codes for a hydrophilic
residue. A triplet codon with middle bases cytosine (C) or
guanine (G) encode residues that are relatively neutral and
with similar hydropathy scores. Hydropathy is an index ofthe
affinity of an aminoacid for a polar environment; hydrophilic
residues yielding a more negative score, while hydrophobic
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residues exhibit more positive scores. Kyte and Doolittle
(1982) conceived a hydropathy scale that is widely used
(Kyte, J., and Doolittle, R. F., J. Mol. Biol. 5:105-32 (1982)).
The observedrelationship between the middle base ofatriplet
codon and residue hydropathy entails that peptides encoded
by complementary DNA will exhibit complementary, or
inverted, hydropathic profiles. It was proposed that because
two peptide sequences encoded in complementary DNA
strands display inverted hydropathic profiles, they may form
amphipathic secondary structures, and bind to one another
(Bost, K. L., et al., Proc. Natl. Acad. Sci. USA 82:1372-75
(1985)). Complementary peptides have been reported to form
binding complexes with their “sense” peptide counterparts
for a numberofdifferent systems (Root-Bernstein, R.S., and
Holsworthy, D. D., J. Theor. Biol. 190:107-19 (1988)). For
example, Gho and Chae describe peptide antagonists of
human angiogenin that are complementary peptides encoded
by the antisense RNA sequence correspondingto the receptor
bindingsite ofangiogenin (Gho,Y. S., and Chae, C. B. J. Biol.
Chem. 272(39):24294-99 (1997)). Ghiso et al. describe a
peptide complementary to a region of cystatin C that exhibits
inhibitory activity (Ghiso, J., et al., Proc. Natl. Acad. Sci.
USA 87(4):1288-91 (1990)), and Bost and Blalock describe
the production of anti-idiotypic antibodies by immunization
with a pair of complementary peptides (Bost. K. L., and
Blalock, J. E., J. Molec. Recognit. 1:179-83 (1989)).
The scope of this analysis for explaining the interactions
between proteins was further developed by Blalock to pro-
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pose a Molecular Recognition Theory (MRT) (Bost, K.L., et
al., Proc. Natl. Acad. Sci. USA 82:1372-75 (1985); Blalock,
J.E., Nature Med. 1:876-78 (1995)). This theory suggests that
a “molecular recognition” code of interaction exists between
peptides that are encoded by complementary strands ofDNA,
based on the observation that such peptides will exhibit
inverted hydropathic profiles. MRT has proved successful for
predicting particular binding interactors.
Blalock suggestedthatit is the linear pattern ofamino acid
hydropathy scores in a sequence(rather than the combination
of specific residue identities), that defines the secondary
structure environment. Furthermore, he suggested that
sequences with inverted hydropathic profiles are complemen-
tary in shape byvirtue of inverse forces that determine their
steric relationships.
Deriving a Complementary Peptide in the 3'-5' Reading
Frame
Asa corollary to his original work, Blalock contendedthat
as well as reading a complementary codon in the usual 5'-3'
direction, reading a complementary codon in the 3'-5' direc-
tion would also yield amino acid sequences that displayed
opposite hydropathic profiles (Bost, K. L., et al., Proc. Natl.
Acad. Sci. USA 82:1372-75 (1985)). This follows from the
observation that the middle base oftriplet codon determines
the hydropathy index ofthe residue it codes for, and therefore
reading a codon in the reverse direction may change the
identity, but not the hydropathic nature of the coded amino
acid (Table 1).
TABLE1
 
The relationships between amino acids and the residues
encoded in the complementary strand
Therelationships between amino acids and the residues encoded in the complementary strand
reading 3'-5'
Amino Complementary Complementary Amino Complementary Complementary
Acid Codon codon Aminoacid Acid codon codon Aminoacid
Alanine GCA CGU Arginine Serine UCA AGU Serine
GCG CGC UCC AGQ Arginine
GCC CGG UCG AGC Serine
GCU CGA UCU AGA Arginine
AGC UCG Serine
AGU UCA Serine
Arginine CGG GCC Alanine Glutamine CAA GUU Valine
CGA GCU Alanine CAG GUC Valine
CGC GCG Alanine
CGU GCA Alanine
AGG UCC Serine
AGA UCU Serine
Aspartic GAC GUC Valine Glycine GGA CCU Proline
Acid GAU AUC Isoleucine GGC CCG Proline
GGU CCA Proline
GGG ccc Proline
Asparagine AAC UUG Leucine Histidine CAC GUG Valine
AAU UUA Leucine CAU GUA Valine
Cysteine UGU ACA Threonine Isoleucine AUA UAU Tyrosine
UGC ACG Threonine AUC UAG Stop
AUU UAA Stop
Glutamic GAA CUU Leucine Leucine CUG GAC Asp
Acid GAG CUG Leucine CUC GAG Glutamic
CUU GAA acid
UUA AAU Glutamic
CUA GAU Acid
UUG AAC Asparagine
CUG GAC Aspartic
Acid
Asparagine
Aspartic
Acid
Lysine AAA UUU Phenylalanine Threonine ACA UGU Cysteine
AAG UUC Phenylalanine ACG UGC Cysteine
ACC UGG Tryptophan
ACU UGA Stop
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TABLE1-continued
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The relationships between aminoacids and the residues
encoded in the complementary strand
The relationships between amino acids and the residues encoded in the complementary strand
reading 3'-5'
Amino Complementary Complementary Amino Complementary Complementary
Acid Codon codon Aminoacid Acid codon codon Aminoacid
Methionine AUG UAC Tyrosine Tryptophan UGG ACC Threonine
Phenylalanine UUU AAA Lysine Tyrosine UAC AUG Methionine
UUC AAG Lysine UAU AUA Isoleucine
Proline CCA GGU Glycine Valine GUA CAU Histidine
ccc GGG Glycine GUG CAC Histidine
CCU GGA Glycine GUC CAG Glutamine
CCG GGC Glycine GUU CAA Glutamine
 
Antibodies and Antibody Producing Cells
NPARagonists as referred to herein encompassantibodies
and antigen-binding fragments thereof that bind to the
complementary peptides described herein and activate the
non-proteolytically activated thrombin receptor. The antibod-
ies as referred to herein can be polyclonal or monoclonal, and
the term “antibody”is intended to encompassbothpolyclonal
and monoclonalantibodies. The terms polyclonal and mono-
clonal refer to the degree of homogeneity of an antibody
preparation, and are not intendedto be limited to particular
methods of production. In one embodiment, the antibody or
antigen-binding fragment is a monoclonal antibody oranti-
gen-binding fragment thereof. The term “monoclonal anti-
body”or “monoclonal antibody composition”as used herein,
refers to a population ofantibody molecules that contain only
one species of an antigen binding site capable of immunore-
acting with a particular epitope of a polypeptide ofthe inven-
tion. A monoclonal antibody composition thus typically dis-
plays a single binding affinity for a particular polypeptide of
the invention with which it immunoreacts.
The term “antibody” as used herein also encompasses
functional fragments of antibodies, including fragments of
chimeric, humanized, primatized, veneered or single chain
antibodies. Functional fragments include antigen-binding
fragments of antibodies that bind to the complementary pep-
tides, wherein complementary peptides are encoded by the
complementofa nucleotide sequence encoding thrombin ora
portion thereof. For example, antibody fragments capable of
binding to a complementary peptide, include, but are not
limited to Fv, Fab, Fab' and F(ab’), fragments. Such fragments
can be produced by enzymatic cleavage or by recombinant
techniques. For example, papain or pepsin cleavage can gen-
erate Fab or F(ab), fragments, respectively. Other proteases
with the requisite substrate specificity can also be used to
generate Fab or F(ab’), fragments. Antibodies can also be
produced ina variety oftruncated formsusing antibody genes
in which one or more stop codons have been introduced
upstream of the natural stop site. For example, a chimeric
gene encoding a F(ab’), heavy chain portion can be designed
to include DNA sequences encoding the CH, domain and
hinge region of the heavy chain.
Single chain antibodies, and chimeric, humanizedorpri-
matized (CDR-grafted), or veneered antibodies, as well as
chimeric, CDR-grafted or veneered single chain antibodies,
comprising portions derived from different species, are also
encompassed by the term antibody. The various portions of
these antibodies can be joined together chemically by con-
ventional techniques, or can be prepared as a contiguous
protein using genetic engineering techniques. For example,
nucleic acids encoding a chimeric or humanized chain can be
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expressed to produce a contiguousprotein. See, e.g., Cabilly
etal., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent
No. 0,125,023 B1; Bosset al., U.S. Pat. No. 4,816,397; Boss
etal., European Patent No. 0,120,694 B1; Neuberger, M.S.et
al., WO 86/01533; Neuberger, M.S.et al., European Patent
No. 0,194,276 B1; Winter, U.S. Pat. No. 5,225,539; Winter,
European Patent No. 0,239,400 B1; Queenet al., European
Patent No. 0451 216 B1; and Padlan, E. A. etal., EP 0519 596
Al. See also, Newman,R.et al., BioTechnology, 10: 1455-
1460 (1992), regarding primatized antibody, and Ladneret
al., U.S. Pat. No. 4,946,778 and Bird, R. E.et al., Science,
242: 423-426 (1988)) regarding single chain antibodies.
Humanized antibodies can be produced using synthetic or
recombinant DNA technology using standard methods or
other suitable techniques. Nucleic acid (e.g., cDNA)
sequences coding for humanizedvariable regions can also be
constructed using PCR mutagenesis methods to alter DNA
sequences encoding a human or humanized chain, such as a
DNA template from a previously humanized variable region
(see e.g., Kamman, M., et al., Nucl. Acids Res., 17: 5404
(1989)); Sato, K., et al., Cancer Research, 53: 851-856
(1993); Daugherty, B. L. et al., Nucleic Acids Res., 19(9):
2471-2476 (1991); and Lewis, A. P. and J. S. Crowe, Gene,
101: 297-302 (1991)). Using theseor other suitable methods,
variants can also be readily produced. In one embodiment,
cloned variable regions can be mutated, and sequences
encoding variants with the desired specificity can be selected
(e.g., from a phagelibrary; see e.g., Krebberet al., U.S. Pat.
No. 5,514,548; Hoogenboom et al., WO 93/06213).
The antibody can be a humanized antibody comprising one
or more immunoglobulin chains [e.g., an antibody compris-
ing a complementarity-determining region (CDR)ofnonhu-
manorigin (e.g., one or more CDRsderived from an antibody
ofnonhumanorigin)] and a framework region derived from a
light and/or heavy chain ofhuman origin (e.g., CDR-grafted
antibodies with or without framework changes)]. In one
embodiment, the antibody or antigen-binding fragment
thereof comprises the light chain CDRs (CDR1, CDR2 and
CDR3)and heavy chain CDRs (CDR1, CDR2 and CDR3) of
a particular immunoglobulin. In another embodiment, the
antibody or antigen-binding fragment further comprises a
human framework region.
Antibodies that are specific for a complementary peptide,
wherein the complementary peptide is encoded by the
complementofa nucleotide sequence encoding thrombin ora
portion thereof, can be raised against an appropriate immu-
nogen, such as a synthetic or recombinant complementary
peptide or a portion thereof. Antibodies can also be raised by
immunizing a suitable host (e.g., mouse) with transfected
cells that express a complementary peptide. Such cells can
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also be usedin a screen for an antibody that bindsthereto (See
e.g., Chuntharapai et al., J. Immunol., 152: 1783-1789
(1994); Chuntharapaiet al., U.S. Pat. No. 5,440,021).
Preparation of Immunizing Antigen, and Polyclonal and
Monoclonal Antibody production can be performed using
any suitable technique (e.g., as exemplified herein). A variety
of methods have been described (see e.g., Kohler et al.,
Nature, 256: 495-497 (1975) and Eur. J. Immunol. 6: 511-519
(1976); Milstein et al., Nature 266: 550-552 (1977);
Koprowskiet al., U.S. Pat. No. 4,172,124; Harlow, E. and D.
Lane, 1988, Antibodies: A Laboratory Manual, (Cold Spring
Harbor Laboratory: Cold Spring Harbor, N.Y.); Current Pro-
tocols In Molecular Biology, Vol. 2 (Supplement 27, Summer
94), Ausubel, F. M.et al., Eds., John Wiley & Sons: New
York, N.Y.), Chapter 11, (1991)). Generally, a hybridomais
produced by fusing a suitable immortal cell line (e.g., a
myelomacell line, such as SP2/0, P3X63Ag8.653 or a het-
eromyeloma) with antibody-producing cells. Antibody-pro-
ducing cells can be obtained from the peripheral blood or,
preferably the spleen or lymph nodes, of humansor other
suitable animals immunized with a complementary peptide.
The fused cells (hybridomas) can be isolated using selective
culture conditions, and cloned by limiting dilution. Cells that
produce antibodies with the desired specificity can be
selected by a suitable assay (e.g., ELISA).
Other suitable methods of producingorisolating antibod-
ies of the requisite specificity (e.g., human antibodies or
antigen-binding fragments) can be used, including, for
example, methods that select recombinant antibody from a
library (e.g., a phage display library). Transgenic animals
capable of producing a repertoire of human antibodies(e.g.,
Xenomouse® (Abgenix, Fremont, Calif.)) can be produced
using suitable methods(see e.g., Jakobovits et al., Proc. Natl.
Acad. Sci. USA, 90: 2551-2555 (1993); Jakobovits et al.,
Nature, 362: 255-258 (1993)). Additional methods that are
suitable for production of transgenic animals capable of pro-
ducing a repertoire ofhuman antibodies have been described
(e.g., Lonberg et al., U.S. Pat. No. 5,545,806; Suraniet al.,
USS. Pat. No. 5,545,807; Lonberg et al., WO 97/13852).
The invention also encompasses bispecific antibodies, or
functional fragments thereof (e.g., F(ab'),), which bind to a
complementary peptide as described herein andat least one
other antigen (e.g., a tumorantigen, a viral antigen). Bispe-
cific antibodies can be secreted by triomas and hybrid hybri-
domas. Generally, triomas are formed by fusion of a hybri-
domaand a lymphocyte(e.g., antibody-secreting B cell) and
hybrid hybridomasare formed by fusion oftwo hybridomas.
Eachof the fused cells (i.e., hybridomas, lymphocytes) pro-
duces a monospecific antibody. However, triomas and hybrid
hybridomas can produce an antibody containing antigen-
binding sites that recognize different antigens. The superna-
tants of triomas and hybrid hybridomas can be assayed for
bispecific antibody using a suitable assay (e.g., ELISA), and
bispecific antibodies can be purified using conventional
methods. (see,e.g., U.S. Pat. No. 5,959,084 (Ring et al.), U.S.
Pat. No. 5,141,736 (Iwasaet al.), U.S. Pat. Nos. 4,444,878,
5,292,668, 5,523,210 (all to Paulus et al.) and U.S. Pat. No.
5,496,549 (Yamazakietal.)).
Angiogenic Growth Factors
An “angiogenic growth factor” is a polypeptide which
stimulates the developmentof blood vessels, e.g., promotes
angiogenesis, endothelial cell growth, stability of blood ves-
sels, and/or vasculogenesis. For example, angiogenic factors,
include, but are notlimited to, e.g.,VEGF and membersofthe
VEGFfamily, P1GF, PDGFfamily, fibroblast growth factor
family (FGFs), TIE ligands (Angiopoietins), ephrins,
ANGPTL3, ANGPTL4,etc. Angiogenic factors also include
polypeptides such as growth hormone, insulin-like growth
factor-I (IGF-I), VIGF, epidermal growth factor (EGF),
CTGF and members ofits family, and TGF-a and TGF-B.
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See, e.g., Klagsbrun and D’Amore, Annu. Rev. Physiol.,
53:217-39 (1991); Streit and Detmar, Oncogene, 22:3172-
3179 (2003); Ferrara & Alitalo, Nature Medicine 5(12):1359-
1364 (1999); Toniniet al., Oncogene, 22:6549-6556 (2003);
and, Sato Int. J. Clin. Oncol., 8:200-206 (2003).
The term “VEGF”(also referred to as “WEGF-A”) as used
herein refers to vascular endothelial cell growthfactorprotein
A. The term “human VEGF”(also referred to as “human
VEGF-A”) as used herein refers to any of the isoforms of
humanvascular endothelial cell growth factor. Described iso-
forms(arising by differential mRNA splicing) include 121,
145, 148, 165, 165b, 183, 189 and 206. See, for example,
Table 2 and Leung et al., Science 246:1306 (1989), and
Houcket al., Mol. Endocrin. 5:1806 (1991). “HumanVEGF”
also includes naturally occurring allelic variants of human
VEGF-A andvariants arising by variations in post-transla-
tional modifications. Table 2 is not intended to be compre-
hensiveorlimiting. Angiogenic growth factors in Table 2 are
human unless otherwise indicated.
TABLE 2
 
Examples ofAngiogenic Growth Factors ofVEGF Family
Angiogenic Growth Chromosome GenBank Refer-
Factor Receptor Location No. ence
Human VEGF-A VEGFRI 6p12 NM__003376
VEGFR2
isoforms: 121
145
148
165
165b
183
189
206
Human VEGF-B VEGFRI 11q13 NM__003377
Human VEGF-C VEGFR3 4q34.1-q34.3_ NM__005429
VEGFR2
Human VEGF-D VEGFR3 Xp22.31 NM__004469
VEGFR2
VEGF-E [Orf virus VEGFR2 AF106020
(D1701)]
VEGF-E [Orf virus VEGFR2 867520(NZ2)]VEGF-E [Orf virus VEGFR2 867522(NZ7)]VEGF-Eyp7/PIGF =VEGFR2 1,2
(chimeric)
VEGF-E/PIGF VEGFR2 3
(chimeric)
PIGF FLT1 14922-q24.3  NM__002632
VEGFRI
isoforms: PIGF1
PIGF2
PIGF3
PIGF4
VEGF-F(viper) VEGFR2 4
D. melanogaster NM__078683 5
PV1
D. melanogaster NM__078775 5
PVF2
D. melanogaster NM__078776 5
PVF3
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Without Significant EnhancementofVascular Permeability and Inflammation,” Arterioscler.Throm.Vasc. Biol. 26; 2019-2026 (2006).
2. Zheng,Y. et al., “Chimeric VEGF-ENZ7/PIGFSpecifically Binding to VEGFR-2 Accel-
erates Skin Wound Healing via Enhancement of Neovascularization,” Arterioscler. Throm.Vasc. Biol. 27: 503-511 (2007).
3. Inoue, N.et al., “Therapeutic Angiogenesis Using Novel Vascular Endothelial Growth
Factor-E/HumanPlacental Growth Factor Chimera Genes,”Arterioscler. Throm.Vasc.Biol.27: 99-105 (2007).
4, Suto, K.et al., “Crystal structures ofnovel vascular endothelial growth factors (VEGF)
from snake venoms:insight into selective VEGF bindingto kinase insert domain-containing
receptor but not to fms-like tyrosine kinase-1,” J. Biol. Chem 280(3): 2126-2131 (2005).
5. Duchek, P., “Guidance of cell migration by the Drosophila PGDF/VEGFreceptor,” Cell107(1): 17-26 (2001).
US 8,334,259 B2
23
Human VEGF-Aexists as a numberof isoformsthat arise
from alternative splicing ofmRNAofa single gene organized
into 8 exons located on chromosome6 (see, e.g., Ferrara N,
Davis Smyth T. Endocr Rev 18:1-22 (1997); and, Henry and
Abraham, Review of Preclinical and Clinical Results with
Vascular Endothelial Growth Factors for Therapeutic Angio-
genesis, Current Interventional Cardiology Reports, 2:228-
241 (2000)). See also, U.S. Pat. Nos. 5,332,671 and 6,899,
882. In one embodiment, VEGF ,,,; is administered in the
methods of the invention (e.g., recombinant human
VEGF | 55). VEGF,¢5, the most abundant isoform,is a basic,
heparin binding, dimeric covalent glycoprotein with a
molecular mass of about 45,000 Daltons (id). VEGF,<5
homodimerconsists of two 165 amino acid chains. The pro-
tein has two distinct domains: a receptor binding domain
(residues 1-110) anda heparin binding domain(residues 110-
165). The domains are stabilized by seven intramolecular
disulfide bonds, and the monomersare linked by twointer-
chain disulfide bonds to form the native homodimer.
VEGF,,, lacks the heparin binding domain (see, e.g., U.S.
Pat. No. 5,194,596), whereas VEGF,9 (see, e.g., U.S. Pat.
Nos.5,008,196; 5,036,003; and 5,240,848) and VEGF.,, are
sequestered in the extracellular matrix.
The term “angiogenic growth factor” also includes those
below in Table 3. The list in Table 3 is not intended to be
comprehensiveorlimiting.
TABLE3
 
Examples of Other Angiogenic Growth Factors
Angiogenin
Angiopoietin-1
Del-1
Acidic fibroblast growth factor (aFGF or FGF-1!)
Basic fibroblast growth factor (bFGF or FGF-23-4)
Fibroblast growth factor 4 (FGF 4)
Follistatin
Granulocyte colony-stimulating factor (G-CSF)
Hepatocyte growth factor (HGF)/scatter factor (SF)
Interleukin-8 (IL-8)
Leptin
Midkine
Platelet-derived endothelial cell growth factor (PD-ECGF)
Platelet-derived growth factor-BB (PDGF-BB) (rhPDGF-BBis
Regranex ®)
Pleiotrophin (PTN)
Progranulin
Proliferin
Transforming growth factor-alpha (TGF-alpha)
Transforming growth factor-beta (TGF-beta)
Tumornecrosis factor-alpha (TNF-alpha)
Vascular endothelial growth factor (VEGF)/vascular permeability
factor (VPF)
Thymosin beta 4 (TB4)
Connective tissue growth factor
Osteopontin
Insulin growth factor (IGF-1)
 
Angiogenic
Growth Chromosome
Factor Receptor Location GenBank No. Reference
PDGFD PDGFR-a@ =11q22.3 NM__025208
PDGFR-B
PDGF-a 7p22 NM__002607
PDGF2 22q12.3-q13.1 NM__002608
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TABLE 3-continued
 
Examples of Other Angiogenic Growth Factors
isoforms:
1 (241
amino acids)
2 (226
amino acids)
PDGFC PDGF-a 4932 NM__016205
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growth factors: first clinical results ofa new treatment ofcoronaryheart disease,” Circulation97; 645-650 (1998).
?Stegmann, T. J. etal., “Induction ofmyocardial neoangiogenesis by human growth factors:
a new therapeutic option in coronary heart disease,” Herz 25: 589-599 (2000).
3Selke, F. W., etal., “Therapeutic angiogenesis with basic fibroblast growth factor: technique
andearly results,” Ann. Thorac. Surg. 65: 1540-1544 (1998).
4Taham, R.J., etal., “Local perivascular delivery of basic fibroblast growth factor in patients
undergoing coronary bypass surgery: results of a phase 1 randomized, double-blind, pla-
cebo-controlledtrial, ’Circulation 100: 1865-1871 (1999).
A “native” polypeptide (e.g., a native angiogenicfactor)is
a polypeptide having the same amino acid sequence as a
polypeptide isolated from a natural source. Thus, a native
polypeptide can have the amino acid sequence ofnaturally
occurring polypeptide from any mammal, e.g., a human. Such
native polypeptides can be isolated from nature or can be
produced by recombinantor synthetic means. The term native
polypeptide encompasses naturally occurring truncated or
secreted forms of the polypeptide (e.g., an extracellular
domain sequence), allelic forms designated as wild type,
naturally occurring variant forms(e.g., alternatively spliced
iso forms) and naturally occurring allelic variants of the
polypeptide.
A “polypeptide variant”(e.g., a polypeptide variant of an
angiogenic factor) means a biologically active polypeptide
having at least about 80% amino acid sequence identity with
the native polypeptide. Such “polypeptide variants” include,
for instance, polypeptides wherein one or more amino acid
residues are added,or deleted, at the N- and/or C-terminus of
the polypeptide relative to a native polypeptide. Ordinarily, a
polypeptide variant will have at least about 80% amino acid
sequenceidentity, or at least about 90% amino acid sequence
identity, or at least about 95% or more amino acid sequence
identity with the native polypeptide. Polypeptide variants
include polypeptides that comprise one or more amino acid
substitutions, additions or deletions, or combinations of any
ofthese differences from the native polypeptide. Polypeptide
variants can have,for instance, several, such as 5 to 10, 1 to 5,
or 4, 3, 2 or 1 aminoacids substituted, deleted, or added, in
any combination, compared to native polypeptides. In one
embodiment, variants have silent substitutions, additions
and/or deletions that do not significantly alter the properties
and activities of the polypeptide compared to the native
polypeptide. Polypeptide variants can also be modified
polypeptides in which one or more aminoacid residues are
modified. Polypeptide variants canbe preparedby a variety of
methods well knownin the art. Polypeptide variants differing
by amino acid sequence from a native polypeptide can be
prepared by mutations in the encoding DNA. Polypeptide
variants also include polypeptides that differ from native
polypeptides in glycosylation or other post-translational
modification.
A polypeptide variant can be prepared, for instance, by
site-directed mutagenesis of nucleotides in the DNA encod-
ing the native polypeptide or by phage display techniques,
thereby producing DNA encodingthe variant, and thereafter
expressing the DNA in recombinantcell culture.
Aminoacid deletions generally range from about 1 to 30
residues, optionally 1 to 10 residues, optionally 1 to 5 or less,
and typically are contiguous.
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Aminoacid sequence additions include amino- and/or car-
boxyl-terminal fusions offrom oneresidueto polypeptides of
essentially unrestricted length as well as intrasequenceinser-
tions of single or multiple amino acid residues. Intrasequence
additions (1.e., additions within a native polypeptide
sequence) may range generally from about 1 to 10 residues,
optionally 1 to 5, or optionally 1 to 3. An example of a
terminal insertion includes a fusion of a signal sequence,
whether heterologous or homologousto the hostcell, to the
N-terminusto facilitate the secretion from recombinanthosts.
Additional polypeptide variants are those in whichat least
one amino acid residue in the native polypeptide has been
removed and a different amino acid residue inserted in its
place (substitution). Conservative substitutions in polypep-
tide variants of an angiogenic growth factor may be madein
accordancewith those shown in Table 4, wherein both exem-
plary and preferred substitutions are conservative substitu-
tions in polypeptide variants of an angiogenic growth factor.
Polypeptide variants can also comprise unnatural amino acids
as described herein.
Aminoacids may be grouped according to similarities in
the properties oftheir side chains (A. L. Lehninger, Biochem-
istry, second ed., pp. 73-75, Worth Publishers, New York
(1975)):
(1) non-polar: Ala (A), Val (V), Leu (L), Ile (1), Pro (P), Phe
(F), Trp (W), Met (M)(2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr
(Y), Asn (N), Gln (Q)
(3) acidic: Asp (D), Glu (E)
(4) basic: Lys (K), Arg (R), His (H)
Alternatively, naturally occurring amino acids may be
divided into groups based on commonside-chain properties:
(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
 
TABLE 4
Original Exemplary Preferred
Residue Substitutions Substitutions
Ala (A) Val; Leu; Ile Val
Arg (R) Lys; Gln; Asn Lys
Asn (N) Gln; His; Asp; Lys; Arg Gln
Asp (D) Glu; Asn Glu
Cys (C) Ser; Ala Ser
Gln (Q) Asn; Glu Asn
Glu (E) Asp; Gln Asp
Gly (G) Ala Ala
His (H) Asn; Gln; Lys; Arg Arg
Ile (1) Leu; Val; Met; Ala; Phe; Norleucine Leu
Leu (L) Norleucine;Ile; Val; Met; Ala; Phe lle
Lys (K) Arg; Gln; Asn Arg
Met (M) Leu; Phe;Ile Leu
Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
 
“Naturally occurring amino acid residues”(i.e. amino acid
residues encoded by the genetic code) may be selected from
the group consisting of: alanine (Ala); arginine (Arg); aspar-
agine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine
(Gin); glutamic acid (Glu); glycine (Gly); histidine (His);
isoleucine (Ile): leucine (Leu); lysine (Lys); methionine
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(Met); phenylalanine (Phe); proline (Pro); serine (Ser); threo-
nine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val).
A “non-naturally occurring amino acid residue”refers to an
amino acid residue, other than those naturally occurring
amino acid residues listed above, which can be bound to
adjacent amino acid residues(s) in a polypeptide chain
through peptide bonds. Examples of non-naturally occurring
aminoacid residues include, e.g., norleucine, ornithine, nor-
valine, homoserine and other amino acid residue analogues
such as those described in Ellman et al. Meth. Enzym. 202:
301-336 (1991) and US Patent application publications
20030108885 and 20030082575.
“Percent (%) amino acid sequence identity” herein is
defined as the percentage of amino acid residues in a candi-
date sequence of an angiogenic growth factor that are identi-
cal with the aminoacid residues in a selected sequence,after
aligning the sequences and introducing gaps, if necessary, to
achieve the maximum percent sequence identity, and not
considering any conservative substitutions as part of the
sequence identity. Alignment for purposes of determining
percent amino acid sequence identity can be achieved in
various waysthat are within the skill in the art, for instance,
using publicly available computer software such as BLAST,
BLAST-2, ALIGN,ALIGN-2 or Megalign (DNASTAR)soft-
ware. Those skilled in the art can determine appropriate
parameters for measuring alignment, including any algo-
rithms needed to achieve maximal alignment over the full
length of the sequences being compared.
For purposesherein, the % aminoacid sequenceidentity of
a given amino acid sequence A to, with, or against a given
amino acid sequence B (which can alternatively be phrased as
a given aminoacid sequenceA that has or comprises a certain
% amino acid sequenceidentity to, with, or against a given
amino acid sequence B)is calculated as follows: 100 times
the fraction X/Y where X is the number of aminoacidresi-
dues scored asidentical matches by alignmentofA and B, and
whereYisthe total number ofamino acid residues in B. It will
be appreciated that where the length of amino acid sequence
A is not equalto the length of amino acid sequence B, the %
amino acid sequence identity ofA to B will not equal the %
amino acid sequenceidentity of B to A.
Portions of an angiogenic growth factor include polypep-
tides that are shorter than a correspondingnative polypeptide,
and comprise at least 20 contiguous aminoacid residues of
the corresponding native polypeptide, that share 75% to
100% amino-acid sequenceidentity with the native polypep-
tide. In particular embodiments, the portion shares at least
90% or 95% amino acid sequence identity with the native
polypeptide. Portions of an angiogenic growth factor can be
synthesized, and can have an N-terminal amino group and a
C-terminal carboxy] group as they occur in proteins isolated
from natural sources, or canhave a modified N-terminus(e.g.,
acylated) and/or a modified C-terminus(e.g., amidated). Por-
tions ofan angiogenic growthfactor can be generated through
the expression of genes constructed for the purpose of pro-
ducing the portion. Portions may be cyclic or linear. In all
cases, portions of an angiogenic growth factor haveat least
50% of the biological activity of the corresponding native
polypeptide, as measured by an assay appropriate to measur-
ing the angiogenic activity of the corresponding native
polypeptide.
A numberofassays have been used previously to measure
angiogenic activity and have been described. An angiogenic
growth factor, whetherit is a native polypeptide, polypeptide
variant, portion of an angiogenic growth factor, or fusion
protein of an angiogenic growth factor, can be tested by an in
vitro or in vivo assay to assessits activity, using one or more
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ofthe assays described herein, or other suitable assay such as
those known to persons of ordinary skill in the art. Notall
assays are appropriate to measure the angiogenic activity ofa
given angiogenic growth factor.
A rabbit corneal assay has been described, in which angio-
genic growth factor implanted into cornea stimulates the
growth of new capillaries. See Ziche et al., Lab. Invest.
61:629-634 (1989). An in vitro angiogenesis assay system
allows for observation ofmorphological changes in endothe-
lial cells stimulated by angiogenic growth factor. See Mon-
tesano et al., J. Cell Biol. 97:1648-1652 (1983). Angiogenic
growth activity can also be measured by an assay for cell
growth [Marconciniet al., Proc. Natl. Acad. Sci. USA 96:
9671-9676 (1999)] in responseto the angiogenic growth fac-
tor, or by chemotaxis assays as described in Examples 6 and
7.
A fusion protein ofan angiogenic growth factor comprises
a biologically active native polypeptide or biologically active
portion thereof (as described above) asa first moiety, linked to
second moiety not occurring in the native polypeptide. Thus,
the second moiety can be an aminoacid or polypeptide. The
first moiety can be in an N-terminal location, C-terminal
location or internal to the fusion protein. In one embodiment,
the fusion protein comprises a biologically active polypeptide
that consists ofthe amino acid sequence ofa naturally occur-
ring angiogenic growth factor or biologically active portion
thereofas the first moiety, and a second moiety comprising a
linker sequence andan affinity ligand.
A fusion protein of an angiogenic growth factor can be
produced by a variety of methods. For example, a fusion
protein can be producedbythe insertion of gene encoding an
angiogenic growth factor or portion thereof into a suitable
expression vector. The resulting construct can be introduced
into a suitable host cell for expression. Upon expression,
fusion protein can be purified from a cell lysate by means of
a suitable affinity matrix, for example (see e.g., Current Pro-
tocols in Molecular Biology. Ausubel, F. M.et al., eds., pp.
16.4.1-16.7.8, containing supplements up through Supple-
ment 28, 1994). See, for examples ofVEGFfusion (chimeric)
proteins, Zheng,et al., Arterioscler. Thromb.Vas. Biol. 2006;
26: 2019-2026 and Inoue,et al., Arterioscler. Thromb. Vasc.
Biol. 2007; 27: 99-105.
Angiogenic growth factors can be of humanorigin or of
non-human (preferably mammalian) origin. Human angio-
genic growth factors as well as non-human species homologs
are angiogenic growth factors and can be used in the combi-
nation therapies ofthe invention.A homologpreferably has at
least 70% amino acid sequence identity, more preferably,at
least 80% sequence identity and, even more preferably, at
least 90% sequenceidentity with a human angiogenic growth
factor.
In accordance with the present invention, “angiogenic
growth factors” encompassnative angiogenic growth factors,
portions of angiogenic growth factors, polypeptide variants
of angiogenic growth factors and fusion proteins of angio-
genic growth factors as described above.
Methods of Treatment with NPAR Agonists
The present invention is directed to methods oftreating
endothelial dysfunction at a site in a subject in need thereof
comprising administering vascularly to the subject a thera-
peutically effective amount ofan NPAR agonist, wherein the
site is not an artery injured by angioplasty, a chronic skin
ulcer, a site in need of osteoinduction or a site in need of
cardiac revascularization. The subject may suffer from one or
more of a variety of diseases or conditions that will benefit
from reversing or inhibiting endothelial dysfunction. Such
diseases or conditions may include, but are not limited to,
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hypertension, congestive heart failure, coronary artery dis-
ease,stroke, cerebrovascular disease, peripheral vascular dis-
ease, diabetes, erectile dysfunction, atherosclerosis, asthma,
rheumatoid arthritis, pulmonary hypertension, acute lung
injury, chronic obstructive pulmonary disease (COPD), cystic
fibrosis, inflammatory lung disease, hyperhomocysteinemia,
sickle cell disease, pre-eclampsia, chronic renal failure,
chronic renal dysfunction, renal microvascular disease,
hepatic reperfusion injury, neuropathy, Alzheimer’s disease,
thyroid disease, sepsis, thrombosis, multiple organ failure,
inflammatory bowel disease, and radiation damage. In a spe-
cific embodiment, the disease is hypertension. In another
specific embodiment, the disease is atherosclerosis. In yet
another specific embodiment, the disease is peripheral vas-
cular disease. In still another specific embodiment, the dis-
ease is asthma.
A “subject” is preferably a human, but can also be an
animalin need of treatment with a NPAR agonist disclosed
herein, e.g., companion animals (e.g., dogs, cats, and the
like), farm animals(e.g., cows, pigs, horses and the like) and
laboratory animals(e.g., rats, mice, guinea pigs and the like).
Subjects “in need of treatment” with a NPAR agonist,are
subjects with diseases and/or conditions that can be treated
withNPAR agonists to achieve a beneficial therapeutic and/or
prophylactic result. A beneficial outcome includes a decrease
in the severity of symptoms or delay in the onset of symp-
toms, increased longevity and/or more rapid or more com-
plete resolution of the disease or condition.
An “effective amount”is the quantity ofthe NPAR agonist
that results in an improvedclinical outcome of the condition
being treated with the NPAR agonist compared with the
absence of treatment. The amount of the NPAR agonist
administered will depend on the degree, severity, and type of
the disease or condition, the amount of therapy desired, and
the release characteristics ofthe pharmaceutical formulation.
Tt will also depend on the subject’s health, size, weight, age,
sex and tolerance to drugs. Typically, the agonist is adminis-
tered for a sufficient period of time to achieve the desired
therapeuticeffect. Typically, from about 1 ug per day to about
1 mg per day ofthe NPARagonist (preferably from about 5 ug
per day to about 100 ug per day) is administered to the subject
in need of treatment, especially for a local means of admin-
istration. The NPAR agonist can also be administered at a
dose of from about 0.1 mg/kg/day to about 10 mg/kg/day,
with from about 0.2 mg/kg/day to about 1 mg/kg/day being
preferred, especially for systemic means of administration.
Typical dosages for the NPAR agonists of the invention are
also 5-500 mg/day, preferably 25-250 mg/day, especially for
systemic means of administration. For methods in which a
combination ofNPAR agonist and angiogenic growth factor
are administered to a subject, the angiogenic growth factor
(e.g., VEGF-A) can be administered in a dosage which can be
determined by one ofordinary skill in theart, according to the
nature ofthe disease or disorder, the site oftreatment, the age,
gender, weight and other conditions ofthe subject. Appropri-
ate dosages of angiogenic growth factor are 1 g/kg to 50
mg/kg (e.g., 0.1-20 mg/kg).
“Treating” meansthat following a period of administering
the NPARagonist or composition comprising an NPARago-
nist, a beneficial therapeutic and/or prophylactic result is
achieved, which can include a decrease in the severity of
symptomsor delayin or inhibition ofthe onset of symptoms,
increased longevity and/ormore rapid or more complete reso-
lution of the disease or condition, or other improvedclinical
outcome as measured according to the site that is being
observedor the parameters measuredfor a particular disease
or disorder. “Treating” also includes inhibiting or delaying
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the onsetof a disease, disorder or medical condition, and can
also mean decreasing the probability of developing such dis-
ease, disorder or medical condition, in a subject, wherein the
subject is, for example, a subject whoisat risk for developing
the disease, disorder or condition.
The disclosed NPAR agonists can be administered by any
suitableroute,locally(e.g., topically) or systemically, includ-
ing, for example, by parenteral administration. Parenteral
administration can include, for example, intramuscular, intra-
venous, subcutaneous,or intraperitoneal injection or vascular
administration, and can also include transdermal patch and
implanted slow-release devices such as pumps. Topical
administration can include, for example, creams, gels, oint-
ments or aerosols. Respiratory administration can include,for
example, inhalation or intranasal drops. For certain indica-
tions, it is advantageousto inject or implant an NPAR agonist
directly to the treatmentsite. The NPARagonist canbe advan-
tageously administered in a sustained release formulation.
The NPARagonist can be administered chronically, wherein
the agonistis administered over a long period oftime(at least
60 days, but more typically, for at least one year), at intervals
or by a continuous delivery method, to treat a chronic or
recurring disease or condition.
Administration of a combination comprising therapeutic
agents includes simultaneous (concurrent) administration as
well as consecutive administration in any order over a period
oftreatment time. The agents can be administered together in
one composition or can be administered in separate compo-
sitions. The NPAR agonist can be administered through the
same administration route as the angiogenic growth factor.
The NPARagonist can also be administered througha differ-
ent administration route from that of the angiogenic growth
factor. The NPAR agonist and the angiogenic growth factor
can have the sameor different administration schedules.
The NPARagonists can be administered to the subject in
conjunction with an acceptable pharmaceutical carrier as part
of a pharmaceutical composition. The formulation of the
pharmaceutical composition will vary according to the route
of administration selected. Suitable pharmaceutical carriers
may contain inert ingredients which do not interact with the
compound. The carriers should be biocompatible, i.e., non-
toxic, non-inflammatory, non-immunogenic and devoid of
other undesired reactions at the administration site. Examples
ofpharmaceutically acceptable carriers include, for example,
saline, aerosols, commercially available inert gels, or liquids
supplemented with albumin, methyl] cellulose or a collagen
matrix. Standard pharmaceutical formulation techniques can
be employed, such as those described in Remington’s Phar-
maceutical Sciences, Mack Publishing Company, Easton,Pa.
The compositions used in the present invention to treat
endothelial dysfunction can additionally comprise a pharma-
ceutical carrier in which the thrombin peptide derivative or
NPARagonist is dissolved or suspended. Examples of phar-
maceutically acceptable carriers include, for example, saline,
aerosols, commercially available inert gels, or liquids supple-
mented with albumin, methyl cellulose or a collagen matrix.
Typical of such formulations are gels. Gels are comprised of
a base selected from an oleaginous base, water, or an emul-
sion-suspension base, as previously described. To the base is
added a gelling agent which forms a matrix in the base,
increasing its viscosity to a semisolid consistency. Examples
of gelling agents are hydroxypropyl cellulose, acrylic acid
polymers, and the like. The active ingredients are added to the
formulation at the desired concentration at a point preceding
addition ofthe gelling agent or can be mixedafterthe gelation
process.
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In one embodiment, the NPARagonists are administered in
a sustained release formulation. Polymers are often used to
form sustained release formulations. Examplesofthese poly-
mers include poly a-hydroxy esters such as polylactic acid/
polyglycolic acid homopolymers and copolymers, polyphos-
phazenes (PPHOS), polyanhydrides and poly(propylene
fumarates).
Polylactic acid/polyglycolic acid (PLGA) homo and
copolymers are well known in the art as sustained release
vehicles. The rate of release can be adjusted by the skilled
artisan by variation of polylactic acid to polyglycolic acid
ratio and the molecular weight ofthe polymer (see Anderson,
etal., Adv. Drug Deliv. Rev. 28:5 (1997), the entire teachings
ofwhich are incorporated herein by reference). The incorpo-
ration ofpoly(ethylene glycol) into the polymeras a blend to
form microparticle carriers allows further alteration of the
release profile of the active ingredient (see Cleek et al., /
Control Release 48:259 (1997), the entire teachings ofwhich
are incorporated herein by reference). Ceramics such as cal-
cium phosphate and hydroxyapatite can also be incorporated
into the formulation to improve mechanical qualities.
PPHOSpolymers contain alternating nitrogen and phos-
phorous with no carbon in the polymer backbone, as shown
below in Structural Formula (ID):
|N=P|R
n
The properties of the polymer can be adjusted by suitable
variation of side groups R and R' that are bonded to the
polymer backbone. For example, the degradation ofand drug
release by PPHOScanbe controlled by varying the amount of
hydrolytically unstable side groups. With greater incorpora-
tion of either imidazoly] or ethylglycol substituted PPHOS,
for example, an increase in degradation rate is observed (see
Laurencin et al., J Biomed Mater. Res. 27:963 (1993), the
entire teachings of which are incorporated herein by refer-
ence), thereby increasing the rate of drug release.
Polyanhydrides, shown in Structural Formula (III), have
well defined degradation and release characteristics that can
be controlled by including varying amounts of hydrophobic
or hydrophilic monomerssuch as sebacic acid and 1,3-bis(p-
carboxyphenoxy)propane(see Leonget al., J. Biomed. Mater.
Res. 19:941 (1985), the entire teachings of which are incor-
porated herein by reference). To improve mechanical
strength, anhydrides are often copolymerized with imides to
form polyanhydride-co-imides. Examples ofpolyanhydride-
co-imides that are suitable for orthopaedic applications are
poly(trimellitylimido-glycine-co-1,6-bis(carboxyphenoxy)
hexane and pyromellityimidoalanine: 1,6-bis(p-carboxyphe-
noxy)hexane copolymers.
0 0I IO—C—R—
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Injectable delivery formulations may be administered
intravenously or directly at the site in need of treatment. The
injectable carrier may be a viscoussolutionor gel.
qd)
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Delivery formulations include physiologicalsaline, bacte-
riostatic saline (saline containing about 0.9% mg/mL benzyl
alcohol), phosphate-buffered saline, Hank’s solution, Ring-
er’s-lactate, or liquids supplemented with albumin, methyl
cellulose, or hyaluronic acid. Injectable matrices include
polymersofpoly(ethylene oxide) and copolymersofethylene
and propylene oxide (see Caoet al., J. Biomater. Sci 9:475
(1998) and Simset al., Plast Reconstr. Surg. 98.843 (1996),
the entire teachings of which are incorporated herein byref-
erence).
Methodsfor encapsulating compositions (such as in a coat-
ing of hard gelatin or cyclodextran) are knownin the art
(Baker, et al., “Controlled Release of Biological Active
Agents”, John Wiley and Sons, 1986).
Ointments are typically prepared using an oleaginousbase,
e.g., containing fixed oils or hydrocarbons, such as white
petrolatum or mineraloil, or an absorbentbase, e.g., consist-
ing of an absorbent anhydrous substance or substances, for
example anhydrouslanolin. Following formationofthe base,
the active ingredients are added in the desired concentration.
Creams generally comprise an oil phase (internal phase)
containing typically fixed oils, hydrocarbons, and the like,
such as waxes, petrolatum, mineral oil, and the like, and an
aqueousphase (continuous phase), comprising water and any
water-soluble substances, such as addedsalts. The two phases
are stabilized by use of an emulsifying agent, for example, a
surface active agent, such as sodium lauryl sulfate; hydro-
philic colloids, such as acacia colloidal clays, beegum, and
the like. Upon formation of the emulsion, the active ingredi-
ents are added in the desired concentration.
Gels contain a base selected from an oleaginous base,
water, or an emulsion-suspension base, as previously
described. To the base is added a gelling agent which formsa
matrix in the base, increasing its viscosity to a semisolid
consistency. Examples of gelling agents are hydroxypropyl
cellulose, acrylic acid polymers, and the like. The active
ingredients are added to the formulation at the desired con-
centration at a point preceding addition ofthe gelling agent.
Diseases and conditions that are treatable with the dis-
closed NPAR agonists are often accompanied by symptoms
and infirmities such as pain and infection. In certain instances
it may be advantageousto co-administer one or more addi-
tional pharmacologically active agents along with an NPAR
agonist to address such issues. For example, managing pain
and inflammation may require co-administration with anal-
gesic or an anti-inflammatory agents. Managing infection
may require co-administration with antimicrobial, antibiotic
or disinfectant agents.
An NPARagonist can be administered to a subject alone or
in combination with one or more other therapeutics, for
example, a cholesterol-lowering agent, an anti-hypertensive
agent, a beta-blocker, an anti-coagulent, a thrombolytic
agent, an analgesic, an anti-inflammatory agent, an anti-
plaque agent, insulin, a nitric oxide generating agent, an
antiviral agent or an antibiotic. In one method, an NPAR
agonist can be administered to a subject in combination with
arginine, for example, with arginine as an oral nutritional
supplement.
Thrombin peptide derivatives and modified thrombin pep-
tide derivatives can be synthesized by solid phase peptide
synthesis (e.g., BOC or FMOC) method, by solution phase
synthesis, or by other suitable techniques including combi-
nations of the foregoing methods. The BOC and FMOC
methods, which are established and widely used, are
described in Merrifield, £ Am. Chem. Soc. 88:2149 (1963);
Meienhofer, Hormonal Proteins and Peptides, C. H. Li, Ed.,
Academic Press, 1983, pp. 48-267; and Barany and Merri-
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field, in The Peptides, E. Gross and J. Meienhofer, Eds.,
Academic Press, New York, 1980, pp. 3-285. Methods of
solid phase peptide synthesis are described in Merrifield, R.
B., Science, 232: 341 (1986); Carpino, L. A. and Han, G. Y.,
J. Org. Chem., 37: 3404 (1972); and Gauspohl, H.et al.,
Synthesis, 5: 315 (1992)). The teachings of these six articles
are incorporated herein by reference in their entirety.
Thrombin peptide derivative dimers can be prepared by
oxidation of the monomer. Thrombin peptide derivative
dimers can be prepared by reacting the thrombin peptide
derivative with an excess of oxidizing agent. A well-known
suitable oxidizing agentis iodine.
A “non-aromatic heterocyclic group” as used herein,is a
non-aromatic carbocyclic ring system that has 3 to 10 atoms
and includesat least one heteroatom, such as nitrogen, oxy-
gen, or sulfur. Examples ofnon-aromatic heterocyclic groups
include piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl,
thiomorpholinyl.
The term “aryl group” includes both carbocyclic and het-
erocyclic aromatic ring systems. Examples of aryl groups
include phenyl, indolyl, furanyl and imidazolyl.
An “aliphatic group”is a straight chain, branchedor cyclic
non-aromatic hydrocarbon. An aliphatic group can be com-
pletely saturated or contain one or more units ofunsaturation
(e.g., double and/or triple bonds), but is preferably saturated,
ie., an alkyl group. Typically, a straight chained or branched
aliphatic group has from 1 to about 10 carbon atoms, prefer-
ably from 1 to about 4, and a cyclic aliphatic group has from
3 to about 10 carbon atoms, preferably from 3 to about 8.
Aliphatic groups include, for example, methyl, ethyl, n-pro-
pyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, cyclo-
pentyl, hexyl, cyclohexyl, octyl and cyclooctyl.
Suitable substituents for an aliphatic group, an aryl group
or anon-aromatic heterocyclic group are those which do not
significantly lower therapeutic activity of the NPAR agonist,
for example, those found on naturally occurring aminoacids.
Examples include —OH, a halogen (—Br, —-Cl, —I and
—F), —O(R,), —O—CO—{R,), —CN, —NO,, —COOH,
—0O, —NH,—NH(R,), —N(R,)2,, —COO(R,), —CONH,,
—CONH(R,), —CON(W).,, —SH, —S(R,), an aliphatic
group, an aryl group and a non-aromatic heterocyclic group.
Each R, is independently an alkyl group or an aryl group. A
substituted aliphatic group can have more than one substitu-
ent.
The invention is illustrated by the following examples
which are not intended to be limiting in any way.
Example 1
Materials and Methods
Endothelial Cell Culture
Human coronary artery endothelial cells (HCAEcells,
Cambrex Bio Science Walkersville, Walkersville, Md.) were
cultured in 5% CO2 at 37° C. in endothelial cell growth
medium (EGM) supplemented with 2% fetal bovine serum
and Single Quot supplements (Clonetics, San Diego, Calif;
containing epidermal growth factor, hydrocortisone, vascular
endothelial growth factor, fibroblast growth factor, insulin
growth factor, ascorbic acid, heparin, gentamycin, and
amphotericin B). Cells were used between passages 4 and 6
for these studies. HCAE cells were plated at a density of
50,000 cells per well in 12-well plates and were grownfor 3
days to reach confluency. Two-day post-confluent cells were
treated with TNFa or TP508. Cells were then incubated in
normoxic or 1% hypoxic conditions for the indicated times.
In some experiments, cells were pretreated with TP508 for 1
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h before TNFa. stimulation. For RNA extraction, HCAEcells
were cultured in 6-well plates.
RT-PCR
Total RNA wasisolated using an Ambionisolation kit as
described by the manufacturer.
RT-PCR for eNOS was performed by Ready-to-Go RT-
PCR Beads (Amersham Biosciences) using a two-step pro-
tocol. First, cDNA synthesis was achieved by incubating 1 ug
total RNA with 1 ug random hexamers(pdN6)as primers and
M.-MuLVreverse transcriptase at 42° C. for 60 min. Then,
after heating at 95° C. for 5 min, PCR wascarried out per-
forming 25 or 30 cycles of denaturation (95° C. for 30 s),
annealing (62° C. for 30 s), and extension (72° C.for 30 s),
ending with a single final extension at 72° C. for 7 min. The
sequences for human eNOSprimers were as follows: sense
5'-GCA CCG GCA TCA CCA GGAAGA AGA-3' (SEQ ID
NO:35) and antisense 5'-CCG CCG CCA AGA GGA CAC
CAG T-3' (SEQ ID NO:36) (Sitges, M.et al., Int. J. Cardiol.
105(1):74-79, 2005). 18S primers (Ambion) were used to
amplify 18S ribosomal RNA as an internal normalization
control. PCR-amplified products were visualized by 1% aga-
rose gel electrophoresis.
SYBRGreen Real-Time PCR
Real time quantitative PCR was used to determinerelative
expression of eNOS mRNAin endothelial cells treated with
TP508 orTNF. Samples were coded to provide blinded analy-
sis. One pg of total RNA wasreverse-transcribed using Taq-
man Reverse Transcription Reagents Kit (ABI) as specified
by the manufacturer. Quantitative PCR amplifications were
done using 2 wl of cDNA in a total volume of 25 wl using
SYBRgreen probes in the SYBR Green PCR Master Mix
(ABI). All PCR assays were run in the ABI Prism 7000
Sequence Detection System. The SYBR green PCR primers
were as follows: human eNOSsense: 5'-GCG GCT GCA
TGA CAT TGA G-3' (SEQ ID NO:37), antisense: 5'-GTC
GCG GTA GAGATG GTC AAGT-3' (SEQ ID NO:38). The
reverse-transcribed cDNA sample cycle threshold values
were determined from triplicate samples and normalized to
the 18S “housekeeping”gene.
Western Blot Analysis
The cell lysates were subjected to SDS-PAGE in a 10%
polyacrylamide gel and transferred to a nitrocellulose mem-
brane (0.2-uum,Invitrogen). After blocking with 5% milk, the
membrane was incubated overnight at 4° C. with primary
antibodies against phospho-eNOS (Ser 1177) and eNOS
(Cell Signaling Technology, Beverly, Mass.), human type-1
arginase (clone 9C5) (Cell Sciences, Canton, Mass.), or
GAPDH (Santa Cruz Biotechnology, Santa Cruz, Calif:).
HRP-conjugated anti-mouse or anti-rabbit antibodies (Cell
Signaling Technology) were used as secondary antibodies
(ARP, horseradish peroxidase). The immunoblots were
developed using Immobilon Western Detection Reagents
(Millipore Corporation).
Example 2
TP508 Blocks TNFa Induced Upregulation of
Arginase 1
Asdescribed above, ED andloss ofNO dependentsignal-
ing can arise either from a decrease in NOSactivity or by an
increase in arginase activity that depletes cellular levels of
L-arginine. In both hypoxia and inflammation, it has been
reported that the level of TNFa is elevated and is thought to
contribute to ED by affecting one or both ofthese NO related
activities. To evaluate the potential effects of TP508 on ED,
we cultured early passage human coronary artery endothelial
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cells (HCAEcells) under normoxic conditions and treated
them with TNFeaalone or with the combination ofTNFa and
TP508.
Western blots of HCAEcell lysates, using antibody spe-
cific for human type-1 arginase showed that TNFa treatment
caused a significant increase in the expression of arginase 1
(ARG1) relative to control cultures (FIG. 1). As shown in
FIGS.1 and 2, TP508 treatment alone had no effect onARG1
expression, but completely blocked the TNFa-induced
increase inARG] expression. The TP508 inhibition ofTNFa
stimulated ARG1 expression is dose dependent with half
maximalinhibition occurring at a TP508 concentration of 10
ug/ml (FIG. 2). Therefore, TP508 appears to block TNFa-
inducedsignals that lead to an increase inARG1. This inhibi-
tory effect of TP508 appears to be specific for a subset of
TNFa effects, since TNFa stimulated phosphorylation of
Erk1/2 and p70 S6 kinase were not inhibited by TP508.
Example 3
TP508 Stimulates eNOS Expression and eNOS
Phosphorylation
Western blots of HCAEcell lysates, using antibody spe-
cific for eNOS phosphorylated at $1177 showed that TNFa
treatment, or exposureofcells to hypoxic conditions (1% O,)
for 24 h, reduced the expression of eNOS by 65% and 45%,
respectively, relative to normoxic controls (FIG. 3). As
shown, TP508 prevented the decreased expression of eNOS
caused by hypoxia to retain eNOSexpressionlevels at levels
similar to those seen in cells cultured under normoxic condi-
tions. In contrast, TP508 addition together with TNFa was
not able to inhibit the TNFa induced decrease in eNOS
expression (not shown). Under normoxic and hypoxic condi-
tions, TP508 increased eNOSphosphorylation relative to nor-
moxic and hypoxic control cultures 1.8-fold and 2.5-fold,
respectively (FIG. 3). Although someofthis phosphorylation
may be due to increased expression of eNOS,the increased
phosphorylation cannot be explained by increased expression
alone. Additional experiments examiningthe effect ofTP508
on eNOSexpression and phosphorylation in cells cultured
under normoxic conditions confirmed that TP508 stimulated
eNOSphosphorylation and showed that this effect is dose
dependent with halfmaximalresponse at ~10 ug/ml(FIG.4).
Example 4
TP508 Upregulates eNOS mRNA
Consistent with the protein expression data, RT-PCR
analysis of mRNA from HCAEcells showed that TP508
upregulates eNOS mRNAexpression (FIG.5). This effect of
TP508 is shown at 25 cycles of RI-PCR where an eNOS
mRNAbandis seen in TP508-treated cells, but not in control
cells. In contrast, TNFa treatment drastically decreased
expressionrelative to controls as demonstrated after 30 cycles
ofRT-PCR.To quantify this effect ofTP508, we used SYBR
Green real-time PCR analysis of reverse transcribed mRNA
samples. As shown in FIG.6, after 24 h of culture under
normoxic conditions, TP508 increased the level of eNOS
mRNA by 40% relative to controls (p<0.05). In contrast,
TNFa decreased the eNOS mRNAlevel by ~80%. A 24-hour
exposureofthe cells to hypoxia (1% oxygen) also decreased
the control levels ofeNOS mRNAby ~60%. TP508 treatment
of these cells partially prevented the hypoxia induced
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decrease. As shown, TP508 treated hypoxic cells had eNOS
mRNA levels ~40% over those of hypoxic control cells
(p<0.05).
Example 5
TP508 Potentiates the Ability ofVEGF to Signal
eNOSPhosphorylation
Human coronary artery endothelial (HCAE)cells (Lonza
Walkersville, Inc., Walkersville, Md.) were cultured in the
presence or absence of TP508 [50 ug/ml] in normoxic and
hypoxic [1% O,] conditions for 24 h and then stimulated with
the angiogenic growth factor, human VEGF[50 ng/ml] for 1
or 5 min. HumanVEGF-induced eNOSactivation was deter-
mined by Western blotting using an antibody recognizing the
activated form of eNOS (phosphorylated at $1177) (Cell
Signaling, Danvers, Mass.). The membrane wasre-probed
with anti-GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) antibody to show equal protein loading. A bar graph
representing densitometric analysis of the activated eNOS
Western blot after different treatments is shown in FIG.8.
As shown in FIG. 8, in normoxic cells, human VEGF
inducestransient phosphorylation ofeNOSon serine 1177 to
activate the enzyme which is maximum at 1 minute (2-fold)
and has declined after 5 minutes stimulation. If cells were
pretreated with TP508prior to humanVEGFstimulation, the
phosphorylation of eNOS wasprolonged and remained near
maximum stimulation for 5 minutes. Thus, TP508 potentiates
the ability of human VEGFto signal eNOS phosphorylation
by extending the period of maximalstimulation.
In hypoxic cells (cultured in 1% O, for 24 hours), the level
of human VEGF-stimulated eNOS phosphorylation is
decreased ~4 fold at 1 min treatment compared to normoxic
cells. Thus, hypoxia significantly reduces human VEGF-
stimulated activation of eNOS. However, hypoxic cells pre-
treated with TP508 showed humanVEGF-inducedactivation
of eNOSatlevels equivalent to that seen in normoxic cells.
Thus, TP508 treatment ofhypoxic cells restores the ability of
human VEGFto stimulate eNOS activation to the level
observed in normoxiccells.
Example 6
TP508 Enhances Endothelial Cell Migration towards
VEGF
The ability of a test substance to attract endothelial cells
and stimulate their migration through pores in the membrane
is one ofseveral tests to determine the angiogenic potential of
test substances. FIG. 9A showsthe design of experiments to
measure migration ofendothelial cells toward a chemoattrac-
tant. Prior to migration assay, cells were cultured with or
without TP508 to determine the effect ofTP508 on endothe-
lial migration.
Human coronary artery endothelial (HCAE)cells (Lonza
Walkersville, Inc., Walkersville, Md.) were cultured in the
absence(control) or presence ofTP508 [50 ug/ml] (“TP pret”
in FIG. 9A and FIG. 9B) for 24 hours. Transmembranecell
migration assays were performed using BD FluoroBlok
inserts (BD Bioscience, Bedford, Mass.) as described by the
vendor. Control or TP508 pretreated cells were addedinto the
top of the inserts. Human VEGF [10 ng/ml] (V) or medium
alone (C) was added to the lower chamberofthe insert plate
as a chemoattractant. Endothelial migration was performed in
normoxic or 1% hypoxic conditions. After a 22-hour incuba-
tion, cells were labeled post-migration with Calcein AM and
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measured by detecting the fluorescence of the cells that
migrated to the underside of the insert membrane.
FIG.9B showsthe effect ofTP508 treatment on migration
of endothelial cells toward the angiogenic factor human
VEGF (human recombinant VEGF-A 165, R&D System,
Minneapolis, Minn.).
The results show that human VEGF stimulates normal
control endothelial cell migration by ~2 fold relative to media
control cells when assayed in normoxic conditions (180%)
and slightly less (~150%) under hypoxic conditionsrelative
to media control cells. Endothelial cells that were pretreated
with TP508 showed cell migration toward human VEGF
~5-fold and ~4 fold relative to media controls when cells were
assayed under normoxic and hypoxic conditions, respec-
tively. TP508 pretreatment, thus, enhances endothelial migra-
tion toward human VEGF2- to 3-fold relative to untreated
control cells. Since this cell migration assay is one measure of
the angiogenic potential of cells, these results demonstrate
that TP508 treatment more than doubles the angiogenic
potential of human VEGF for endothelial cells under nor-
moxic conditions as well as under hypoxic conditions where
angiogenic responses to homan VEGFare diminished.
Example 7
TP508 Increases Angiogenic Response of
Endothelial Cells toward Human VEGF
Invasion of endothelial cells through a Matrigel matrix is
one ofmany assays used to determine the angiogenic poten-
tial of test substances and is thought to be more predictive of
angiogenesis in vivo than a simple chemotactic assay through
open membraneporessince the cells must degrade and invade
the matrix to move into and through the pores in the mem-
brane. FIG. 10A showsthe design of experiments to measure
invasion of endothelial cells through Matrigel toward a
chemoattractant.
Human coronary artery endothelial (HCAE) cells (Lonza
Walkersville, Inc., Walkersville, Md.) were cultured in the
absence(control) or presence ofTP508 [50 ug/ml] (TP pret)
for 24 hours. Endothelial cell invasion assays were performed
using BD BioCoat™ Angiogenesis System (BD Bioscience,
Bedford, Mass.) which utilizes FluoroBlok inserts coated
with BD Matrigel Matrix (BD Bioscience, Bedford, Mass.).
Control or TP508 pretreated cells were added into the top of
the inserts. Medium containing human VEGF [10 ng/ml
human recombinant VEGF-A 165aa, R&D System, Minne-
apolis, Minn.] (V) or medium alone (C) was added to the
lower chamber of the insert plate as a chemoattractant to
determine angiogenic response to human VEGF.Endothelial
cell invasion was performed in normoxic or hypoxic (1% O,)
conditions. After 22 hours of incubation, cells were labeled
post-invasion with Calcein AM and measured by detecting
the fluorescenceofthe cells that migrated to the underside of
insert membrane.
FIG. 10B showsthe effect ofTP508 treatment on invasion
of endothelial cells toward human VEGF.Theresults show
that control endothelial cells assayed in normoxic conditions
or under hypoxic conditions are not stimulated by human
VEGFto degrade Matrigel and migrate through the mem-
brane toward human VEGF.In contrast, endothelial cells that
were pre-incubated with TP508 show increased invasive
properties over control cells that were not pretreated with
TP508.In addition, these cells now respond to hamanVEGF
(~50% moreinvasion than observed in TP508pretreated cells
without human VEGFand nearly twice as much invasion as
control cells toward VEGF). These results demonstrate the
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ability ofTP508 treatmentto increase the ability of endothe-
lial cells to respond angiogenically to homan VEGF under
conditions where non-TP508 treated control cells do not
respondatall to homan VEGFtreatment.
Example 8
Effects of TP508 on VEGF mRNAExpression in
Normoxic and Hypoxic HCMVECells
Humancardiac microvascular endothelial (HCMVE)cells
were treated withVEGF (10 ng/ml) (V) or TP508 (50 ug/ml)
(TP) and cultured in normoxic or 1% hypoxic conditions for
24h. Real-time PCR analyses show changes in steady-state
levels ofVEGF mRNAafter treatment. Data from one experi-
ment performed in triplicate are shown in FIG. 11 as
means+SD. *p<0.01 compared to control (C) cells in nor-
moxia. *p<0.01 compared to control (C) cells in hypoxia.
Real-time PCR analyses showed that VEGF stimulation
decreased VEGF mRNA expression (2-fold) compared to
control cell in normoxic condition. As expected, hypoxia
increased VEGF mRNA (2.4-fold) compared to normoxic
control cells. TP508 treatment had no effect on steady-state
level ofVEGF mRNA in normoxic cells. However, hypoxic
cells treated with TP508 expressed ~4-fold and ~10-fold
higher levels ofVEGF mRNA expression compared to con-
trol hypoxic or control normoxiccells, respectively (FIG. 11).
In contrast, VEGF stimulation had no effect, or decreased
VEGF mRNAin hypoxic cells. By this experiment, TP508
enhancesthe effect of hypoxia to up-regulate VEGF expres-
sion.
Example 9
Effect of TP508 Pre-Treatment on Carbachol
Induced Relaxation
Rat aortic rings (endothelial cell layer intact) were pre-
pared. Rings were treated with no TP508 (control) or 1 mM
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treated rings showedincreasedrelaxationrelative to controls.
Furthermore, TP508 pre-treatment leads to a sigmoidal car-
bachol dose response curve. The control rings produced a
linear carbachol dose response curve.
Example 10
Studies on Human Endothelial Cells
HMVEC (Human Microvascular Endothelial Cells)
Experiments using microarrays showed TP508 to prevent
the increase in arginase 1 (ARG1) and decrease in endothelial
nitric oxide synthase (eNOS) expression expected response
to hypoxia. Studies on HMVECsare relevant to peripheral
vascular disease, and renal vascular disease, for example.
HAE (Human Aortic Endothelial Cells)
HAEcells were used to study downstream regulatory ele-
ments. After 30 minutes of incubation under normoxic con-
ditions, TP508 decreased phosphorylation of intracellular
signal-regulating kinase 1 and 2 (ERK 1/2) and the serine/
threonine kinase p70S6, and increased phosphorylation of
focal adhesion kinase (FAK).
HAEcells were treated with tumor necrosis factor alpha
(TNFa), increasing expression ofARG1. Pretreatment with
TP508 inhibited the TNFa-induced increase in ARG1 only.
This suggests that TP508 can reverse cytokine effects on the
nitric oxide (NO) pathway. Under normoxic conditions,
TP508 increased phosphorylated eNOS (p-eNOS) and eNOS
in cells with and without TNFa/hypoxic treatment.
Studies on HAEcells are relevant to hypertension, athero-
sclerosis, aortic stenosis, and aortic aneurysm, for example.
TABLE5
 
HAE SUMMARY
Treatment Responses
Cells treated with
TP508 (normoxic)
Cells pretreated
with TP508, then
TNFa
TP508 treatment
with and without
TNFa
ERK 1/2 activation
decreased
Inhibited the TNFa-
induced increase in
FAKactivation
increased
No effect on p70S6
phosphorylation
p70S6 activation
decreased
Noeffect on ERK1/2
phosphorylation
ARG1
Increased eNOS Increased eNOS
expression activation
 
TP508 for 1 hour. Rings were contracted with 500 nM nore-
pinephrine, followed by increasing doses of carbachol(0, 1,
10, 100, 500, 750, 1000 and 5000 nM). Mean valuestSEM
are shown; n=2 animals.
Norepinephrine contracted rings, with intact endothelium,
relax in response to increasing doses ofcarbachol (Furchgott,
R. F. and Zawadzki, J. V., Nature 288. 373-376 (1980)). If
TP508 is a smooth muscle relaxant, TP508 treatmentprior to
a norepinephrine-carbachol dosing regimen should result in
an increase in carbachol induced relaxation comparedto the
control, i.e., a shift ofthe carbachol dose response curveto the
left relative to the control curve.
FIG. 12 demonstrates that at increased carbachol concen-
trations (greater than 250 nM; rectangular box) TP508 pre-
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HLME (Human Lung Microvascular Endothelial Cells;
Alternatively, HLMVECells)
HLMEcells were tested with VEGF, TP508 and serum-
deprivation. Both lines observed showed increased survival
when treated with both VEGF and TP508. VEGF alone
increased survivalat lower levels, and TP508 alone hadlittle
effect.
VEGF, eNOS, VEGFR1 and VEGFR2 were observed
responding to TP508 treatment under hypoxic and normoxic
conditions. When HLMEcells were studied under normoxic
conditions, only eNOS waspositively regulated by TP508
treatment. When HLMEcells were studied under hypoxic
conditions, all four of these genes were upregulated at the
mRNAlevel over the hypoxic untreated control.
US 8,334,259 B2
39
TABLE6
40
 
HLME SUMMARY
Treatment Responses
Cells were deprived of
serum,treated with VEGF
and TP508
Cells treated with TP508:
Treating with TP508 alone
did not increase cell
survival rate
eNOSexpression was up
Treating with VEGF and
TP508 increased survival
beyond VEGFalone.
VEGF, VEGFR1 and VEGFR2
normoxic regulated expression: no effect
Cell treated with TP508: eNOSexpression was up VEGF, VEGFRI and VEGFR2
hypoxic regulated expression were upregulated
 
Studies on HLMEcells are relevant to asthma, acute lung
injury, pulmonary artery hypertension, cystic fibrosis, and
inflammatory lung disease, for example.
Example 11
Effects on Endothelial Function/Dysfunction in
Isolated Coronary Arterioles
Coronary microvessels (arterioles) were isolated at day 60
from hearts of adult Yucatan swine that had undergone
chronic occlusion of the left circumflex coronary artery
(LCX)using an ameroid constrictor, and from nonischemic
left anterior descending arteries (LAD) as described. Subepi-
cardial arteriolar branches (60-100 um internal diameter and
1 to 1.5 mm in length without branches,in situ) were carefully
dissected from the LAD or LCX.Eacharteriole was cannu-
lated with glass micropipettes and pressurized to 60 cm H,O
intraluminal pressure without flow. Internal diameters of the
vessel were measured throughoutthe experimentusing video
microscopic techniques incorporated with MacLab (ADIn-
struments,Inc) data acquisition system. Following the devel-
opment of tone (spontaneous constriction to about 70% of
maximal diameter), we determined the concentration to
diameterrelationship for endothelium-dependent NO-medi-
ated vasodilators adenosine (0.1 nM to 10 uM)and serotonin
(0.1 nM to 1 uM), ATP sensitive potassium channel opener
pinacidil (0.1 uM to 3 uM), and endothelium-independent
vasodilator sodium nitroprusside (1 nM to 0.1 mM). The
vasodilatory responses to these agonists were established
before and after extraluminal incubation ofarterioles. At the
end ofthe experiments, each vessel was relaxed with 100 uM
sodium nitroprusside in a physiologically balanced calcium-
free salt solution containing ethylenediaminetetraacetic acid
(EDTA, 1 mM)to obtain its maximal diameter at 60 cm H,O
intraluminal pressure. All diameter changes in response to
agonists were normalizedto this dilation and expressed as a
percentage of maximaldilation.
To determine if chronic ischemia in this model of LCX
occlusion created coronary artery endothelial dysfunction
and ifTP508 treatment affected NO signaling, coronary arte-
rioles were isolated from nonischemic branchesofleft ante-
rior descending arteries (LAD) and from occluded, ischemic,
LCX ofTP508- and placebo-treated hearts. The isolated arte-
rioles were then treated ex vivo with adenosine, serotonin,
sodium nitroprusside, or pinacidil. If arterioles have endot-
helial dysfunction with impaired NO production, they should
show diminished vasodilation in response to adenosine and
serotonin (which are endothelium-dependent NO-mediated
vasodilators), but not to sodium nitroprusside and pinacidil,
20
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which relax smooth muscle cells independent of endothelial
cell response by donating NO to activate cyclic GMP and
opening smooth muscle cell ATP-sensitive potassium chan-
nels, respectively.
Ischemicarterioles show significantly diminisheddilation
responses to adenosineor serotonin relative to nonischemic
vessels (FIGS. 13A and 13B). As shown, ischemia causes a
rightward shift in the dose-response curve with ischemic
arterioles requiring an order of magnitude more drug to
achieve the same degree ofdilation as nonischemicarterioles.
This effect of hypoxia was not seen when isolated vessels
were exposed to nitroprusside or pinacidil (FIGS. 13C and
13D). Thus, hypoxic arterioles dilate normally in responseto
NOdelivered via NO donor and to a smooth muscle relaxing
drug, but demonstrate classic endothelial dysfunction with
diminished ability of endothelial cells to produce NO in
response to serotonin and adenosine.
TP508 significantly increased arteriolar response to
adenosine and serotoninrelative to the responsesofarterioles
isolated from ischemic placebo-treated hearts (FIGS. 134A
and 13B). Response to adenosine, in fact, appears to be
restored in arterioles isolated from ischemic TP508-treated
heartsto the level seen in nonischemic control arterioles (FIG.
13A).
To confirm that this TP508 effect on vasodilation repre-
sented a reversal of endothelial dysfunction in these arteri-
oles, we determined the effect of hypoxia and TP508 on the
ability of these arterioles to generate NO andthelevels of
eNOSexpression. As shown in FIG. 13E, NO production by
isolatedarterioles from the ischemic LCX ofplacebo-treated
hearts was decreased relative to nonischemic control arteri-
oles from the LAD.Arterioles from ischemic LCX ofTP508-
treated hearts, however, had levels of NO production that
exceeded the nonischemic control level. PCR analysis of
mRNAfrom alimitednumberofthese arterioles showed that
eNOS mRNAexpression wasdecreased in arterioles from the
ischemic LCX relative to nonischemic control arterioles
(FIG. 13F). Similar to its effect on NO production, TP508
treatment restored eNOS mRNAexpression in ischemic arte-
rioles to a level similar to or greater than that found in nonis-
chemic arterioles. These results suggest that TP508 reverses
endothelial dysfunction in these arterioles by a process that
includes the upregulation of eNOS allowing more NO pro-
duction.
While this invention has been particularly shown and
described with references to example embodimentsthereof, it
will be understood by those skilled in the art that various
changes in form and details may be made therein without
departing from the scope ofthe invention encompassedbythe
appendedclaims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 40
<210> SEQ ID NO 1
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 13
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 1
Arg Gly Asp Ala Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 2
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 15
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 22
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is optionally N-acylated
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 23 is optionally C-amidated
<400> SEQUENCE: 2
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Xaa Gly
1 5 10 15
Asp Ser Gly Gly Pro Xaa Val
20
<210> SEQ ID NO 3
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is unmodified
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 23 is amidated with -NH2
<400> SEQUENCE: 3
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 4
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
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<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 13
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 4
Arg Gly Asp Ala Xaa Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 5
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 14
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 15
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 22
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 5
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Xaa Xaa Gly
1 5 10 15
Asp Ser Gly Gly Pro Xaa Val
20
<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is optionally N-acylated
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 23 is optionally C-amidated
<400> SEQUENCE: 6
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 7
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<400> SEQUENCE: 7
Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10
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<210> SEQ ID NO 8
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 8
Lys Gly Ser Pro Thr Val Thr Phe Thr Gly Ile Pro Cys Phe Pro Phe
1 5 10 15
Ile Arg Leu Val Thr Ser
20
<210> SEQ ID NO 9
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 9
Thr Phe Thr Gly Ile Pro Ser Phe Pro Phe
1 5 10
<210> SEQ ID NO 10
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 10
Arg Pro Met Phe Gly Leu Leu Pro Phe Ala Pro Leu Arg Thr Leu Pro
1 5 10 15
Leu Ser Pro Pro Gly Lys Gln
20
<210> SEQ ID NO 11
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 11
Lys Pro Phe Ala Pro Leu Arg Thr Leu Pro
1 5 10
<210> SEQ ID NO 12
<211> LENGTH: 622
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 12
Met Ala His Val Arg Gly Leu Gln Leu Pro Gly Cys Leu Ala Leu Ala
1 5 10 15
Ala Leu Cys Ser Leu Val His Ser Gln His Val Phe Leu Ala Pro Gln
20 25 30
Gln Ala Arg Ser Leu Leu Gln Arg Val Arg Arg Ala Asn Thr Phe Leu
35 40 45
Glu Glu Val Arg Lys Gly Asn Leu Glu Arg Glu Cys Val Glu Glu Thr
50 55 60
Cys Ser Tyr Glu Glu Ala Phe Gly Ala Leu Glu Ser Ser Thr Ala Thr
65 70 75 80
47
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Asp
Arg
Gly
Cys
Thr
145
Asp
Arg
Pro
Leu
225
Glin
Leu
Trp
Asn
Glu
305
Glin
Gly
Arg
Asp
Ser
385
Phe
Arg
Ile
Leu
465
Tyr
val
Asp
Thr
Gln
130
Thr
Ser
Arg
Ala
Leu
210
Ala
Ala
val
Cys
Tyr
290
Asp
Thr
Leu
Glu
Ala
370
Pro
Leu
Thr
Tyr
His
450
Met
Cys
Lys
Phe
Lys
Asn
115
Leu
His
Ser
Gln
Met
195
Glu
val
Lys
Glu
Tyr
275
Cys
Ser
Phe
Arg
Leu
355
Glu
Gln
Thr
Glu
Glu
435
Pro
Lys
Leu
Gly
Trp
Leu
100
Tyr
Trp
Pro
Thr
Glu
180
Thr
Gln
Thr
Ala
Asn
260
val
Glu
Asp
Phe
Pro
340
Leu
Ile
Glu
Ala
Asn
420
Arg
Arg
Leu
Pro
Arg
500
Ala
85
Ala
Arg
Arg
Gly
Thr
165
Cys
Pro
Cys
Thr
Leu
245
Phe
Ala
Glu
Arg
Asn
325
Leu
Glu
Gly
Leu
Ala
405
Asp
Asn
Tyr
Lys
Asp
485
val
Lys
Ala
Gly
Ser
Ala
150
Gly
Ser
Arg
val
His
230
Ser
Cys
Gly
Ala
Ala
310
Pro
Phe
Ser
Met
Leu
390
His
Leu
Ile
Asn
Lys
470
Arg
Thr
Tyr
Cys
His
Arg
135
Asp
Pro
Ile
Ser
Pro
215
Gly
Lys
Arg
Lys
val
295
Ile
Arg
Glu
Tyr
Ser
375
Cys
Cys
Leu
Glu
Trp
455
Pro
Glu
Gly
Thr
Leu
val
120
Tyr
Leu
Trp
Pro
Glu
200
Asp
Leu
His
Asn
Pro
280
Glu
Glu
Thr
Lys
Ile
360
Pro
Gly
Leu
val
Lys
440
Arg
val
Thr
Trp
Ala
Glu
105
Asn
Pro
Gln
Cys
val
185
Gly
Arg
Pro
Gln
Pro
265
Gly
Glu
Gly
Phe
Lys
345
Asp
Trp
Ala
Leu
Arg
425
Ile
Glu
Ala
Ala
Gly
505
Cys
90
Gly
Ile
His
Glu
Tyr
170
Cys
Ser
Gly
Cys
Asp
250
Asp
Asp
Glu
Arg
Gly
330
Ser
Gly
Gln
Ser
Tyr
410
Ile
Ser
Asn
Phe
Ala
490
Asn
Glu
Asn
Thr
Lys
Asn
155
Thr
Gly
Ser
Gln
Leu
235
Phe
Gly
Phe
Thr
Thr
315
Ser
Leu
Arg
val
Leu
395
Pro
Gly
Met
Leu
Ser
475
Ser
Leu
Thr
Cys
Arg
Pro
140
Phe
Thr
Glin
val
Glin
220
Ala
Asn
Asp
Gly
Gly
300
Ala
Gly
Glu
Ile
Met
380
Ile
Pro
Lys
Leu
Asp
460
Asp
Leu
Lys
Ala
Ala
Ser
125
Glu
Cys
Asp
Asp
Asn
205
Tyr
Trp
Ser
Glu
Tyr
285
Asp
Thr
Glu
Asp
val
365
Leu
Ser
Trp
His
Glu
445
Arg
Tyr
Leu
Glu
Arg
Glu
110
Gly
Ile
Arg
Pro
Gln
190
Leu
Gln
Ala
Ala
Glu
270
Cys
Gly
Ser
Ala
Lys
350
Glu
Phe
Asp
Asp
Ser
430
Lys
Asp
Ile
Gln
Thr
510
Thr
95
Gly
Ile
Asn
Asn
Thr
175
val
Ser
Gly
Ser
val
255
Gly
Asp
Leu
Glu
Asp
335
Thr
Gly
Arg
Arg
Lys
415
Arg
Ile
Ile
His
Ala
495
Trp
Pro
Leu
Glu
Ser
Pro
160
val
Thr
Pro
Arg
Ala
240
Gln
val
Leu
Asp
Tyr
320
Cys
Glu
Ser
Lys
Trp
400
Asn
Thr
Tyr
Ala
Pro
480
Gly
Thr
49
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Ala Asn Val Gly Lys Gly
515
Pro Ile Val Glu Arg Pro
530
Thr Asp Asn Met Phe Cys
545 550
Gly Asp Ala Cys Glu Gly
565
Pro Phe Asn Asn Arg Trp
580
Gly Cys Asp Arg Asp Gly
595
Leu Lys Lys Trp Ile Gln
610
<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<400>
1
<210>
<211>
<212>
<213>
<220>
<223>
<400>
1
<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<400>
SEQ ID NO 13
LENGTH: 12
TYPE: PRT
Glin
val
535
Ala
Asp
Tyr
Lys
Lys
615
Pro
520
Cys
Gly
Ser
Gln
Tyr
600
val
Ser
Lys
Tyr
Gly
Met
585
Gly
Ile
ORGANISM: Artificial SequenceFEATURE:OTHER INFORMATION:
FEATURE:NAME/KEY: VARIANTLOCATION: 2
OTHER INFORMATION:FEATURE:NAME/KEY: VARIANTLOCATION: 4
OTHER INFORMATION:FEATURE:NAME/KEY: VARIANTLOCATION: 11
OTHER INFORMATION:
SEQUENCE: 13
Asp Xaa Cys Xaa Gly Asp
5
SEQ ID NO 14
LENGTH: 10
TYPE: PRT
val
Asp
Lys
Gly
570
Gly
Phe
Asp
Leu Gln Val Val Asn Leu
525
Ser Thr Arg Ile Arg Ile
540
Pro Asp Glu Gly Lys Arg
555 560
Pro Phe Val Met Lys Ser
575
Ile Val Ser Trp Gly Glu
590
Tyr Thr His Val Phe Arg
605
Gln Phe Gly Glu
620
serine esterase conserved sequence
Xaa
Xaa
Xaa
= Ala or Ser
= Glu or Gln
Phe, Met, Leu, His or Val
Ser Gly Gly Pro Xaa Val
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION:
SEQUENCE: 14
SEQ ID NO 15
LENGTH: 10
TYPE: PRT
10
serine esterase conserved sequence
Cys Glu Gly Asp Ser Gly Gly Pro Phe Val
5
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION:
FEATURE:
NAME/KEY: VARIANT
LOCATION: 2
OTHER INFORMATION:
FEATURE:
NAME/KEY: VARIANT
LOCATION: 9
OTHER INFORMATION:
SEQUENCE: 15
Cys Xaa Gly Asp Ser Gly
1 5
10
serine esterase conserved sequence
Xaa
Xaa
= Glu or Gln
Phe, Met,
Gly Pro Xaa Val
10
Leu, His or Val
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<210> SEQ ID NO 16
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide
<400> SEQUENCE: 16
Arg Gly Asp Ala
1
<210> SEQ ID NO 17
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Arg at position 1 is optionally N-acylated
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 14 is optionally C-amidated
<400> SEQUENCE: 17
Arg Gly Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Phe Val
1 5 10
<210> SEQ ID NO 18
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Asp at position 1 is optionally N-acylated
<220> FEATURE:
<223> OTHER INFORMATION: Phe at position 33 is optionally C-amidated
<400> SEQUENCE: 18
Asp Asn Met Phe Cys Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro
20 25 30
Phe
<210> SEQ ID NO 19
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 20
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 27
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<220> FEATURE:
<223> OTHER INFORMATION: Asp at position 1 is optionally N-acylated
<220> FEATURE:
<223> OTHER INFORMATION: Phe at position 33 is optionally C-amidated
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<400> SEQUENCE: 19
Asp Asn Met Phe Cys Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val Met Lys Ser Pro
20 25 30
Phe
<210> SEQ ID NO 20
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 14
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
<400> SEQUENCE: 20
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Xaa Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 21
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<400> SEQUENCE: 21
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Ala Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 22
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is unmodified
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 23 is amidated with -NH2
<400> SEQUENCE: 22
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Ala Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 23
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5, 19
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
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<400> SEQUENCE: 23
Asp Asn Met Phe Xaa Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Xaa Glu Gly Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro
20 25 30
Phe
<210> SEQ ID NO 24
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5, 19
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 20
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 27
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 24
Asp Asn Met Phe Xaa Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Xaa Xaa Gly Asp Ser Gly Gly Pro Xaa Val Met Lys Ser Pro
20 25 30
Phe
<210> SEQ ID NO 25
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<400> SEQUENCE: 25
Asp Asn Met Phe Ala Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Ala Glu Gly Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro
20 25 30
Phe
<210> SEQ ID NO 26
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Asp at position 1 is unmodified
<220> FEATURE:
<223> OTHER INFORMATION: Phe at position 33 is amidated with -NH2
<400> SEQUENCE: 26
Asp Asn Met Phe Ala Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly
1 5 10 15
Asp Ala Ala Glu Gly Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro
20 25 30
Phe
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<210> SEQ ID NO 27
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<400> SEQUENCE: 27
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro Phe Asn Asn Arg Trp
20 25 30
Tyr
<210> SEQ ID NO 28
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 15
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 22
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 28
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Xaa Gly
1 5 10 15
Asp Ser Gly Gly Pro Xaa Val Met Lys Ser Pro Phe Asn Asn Arg Trp
20 25 30
Tyr
<210> SEQ ID NO 29
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is unmodified
<220> FEATURE:
<223> OTHER INFORMATION: Tyr at position 33 is amidated with -NH2
<400> SEQUENCE: 29
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val Met Lys Ser Pro Phe Asn Asn Arg Trp
20 25 30
Tyr
<210> SEQ ID NO 30
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 30
Lys Gly Ser Pro Thr Val Thr Phe Thr Gly Ile Pro Cys Phe Pro Phe
1 5 10 15
Ile Arg Leu Val Thr Ser
20
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<210> SEQ ID NO 31
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 31
Lys Gly Ser Pro Thr Val Thr Phe Thr Gly Ile Pro Ser Phe Pro Phe
1 5 10 15
Ile Arg Leu Val Thr Ser
20
<210> SEQ ID NO 32
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 32
Thr Phe Thr Gly Ile Pro Ser Phe Pro Phe
1 5 10
<210> SEQ ID NO 33
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 33
Arg Pro Met Phe Gly Leu Leu Pro Phe Ala Pro Leu Arg Thr Leu Pro
1 5 10 15
Leu Ser Pro Pro Gly Lys Gln
20
<210> SEQ ID NO 34
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: complementary peptide of domain of thrombin
<400> SEQUENCE: 34
Leu Pro Phe Ala Pro Leu Arg Thr Leu Pro
1 5 10
<210> SEQ ID NO 35
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer
<400> SEQUENCE: 35
gcaccggcat caccaggaag aaga 24
<210> SEQ ID NO 36
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer
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<400> SEQUENCE: 36
cegecgcecaa gaggacacca gt 22
<210> SEQ ID NO 37
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer
<400> SEQUENCE: 37
geggcetgcat gacattgag 19
<210> SEQ ID NO 38
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer
<400> SEQUENCE: 38
gtegeggtag agatggtcaa gt 22
<210> SEQ ID NO 39
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa = Ala, Gly, Ser or S-protected Cys
<400> SEQUENCE: 39
Arg Gly Asp Ala Xaa Glu Gly Asp Ser Gly Gly Pro Phe Val
1 5 10
<210> SEQ ID NO 40
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: thrombin peptide derivative
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 15
<223> OTHER INFORMATION: Xaa = Glu or Gln
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 22
<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<220> FEATURE:
<223> OTHER INFORMATION: Ala at position 1 is unmodified
<220> FEATURE:
<223> OTHER INFORMATION: Val at position 23 is amidated with -NH2
<400> SEQUENCE: 40
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Xaa Gly
1 5 10 15
Asp Ser Gly Gly Pro Xaa Val
20
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Whatis claimed is:
1. A method oftreating hypertension in a subject compris-
ing administering to the subject a therapeutically effective
amount ofa 12 to 23 amino acid thrombin peptide derivative
comprising a serine esterase conserved sequence and a
thrombin binding domain having the sequenceArg-Gly-Asp-
Ala (SEQ ID NO:16).
2. The method of claim 1, wherein the thrombin peptide
derivative comprises an N-terminus which is unsubstituted
and a C-terminus which is unsubstituted or a C-terminal
amide represented by —C(O)NH,and the thrombin peptide
derivative comprises a polypeptide having the amino
sequence of Arg-Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-
Gly-Pro-X,-Val (SEQ ID NO:1), wherein X, is Glu or Gln
and X, is Phe, Met, Leu, His or Val.
3. The method of claim 1, wherein the thrombin peptide
derivative comprises the amino acid sequence of Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2),or a frag-
mentthereof, comprising amino acids 10-18 of SEQ ID NO:
2, whereinX, is Glu or Gln andX, is Phe, Met, Leu, His orVal
and the thrombin peptide derivative comprises an N-terminus
which is unsubstituted and a C-terminus which is unsubsti-
tuted or a C-terminal amide represented by —C(O)NH.
4. The method of claim 2, wherein the thrombin peptide
derivative is the polypeptide H-Ala-Gly-Tyr-Lys-Pro-Asp-
Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-
Gly-Pro-Phe-Val-NH, (SEQ ID NO:3).
5. A methodoftreating hypertension in a subject compris-
ing administering to the subject a peptide dimer comprising
two 12 to 23 amino acid thrombin peptide derivatives which,
independently, comprise a serine esterase conserved
sequence, and a thrombin binding domain having the
sequence Arg-Gly-Asp-Ala (SEQ ID NO: 16); and wherein
the dimeris essentially free ofmonomer.
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6. The method of claim 5, wherein the thrombin peptide
derivatives each comprise an N-terminus which is unsubsti-
tuted; and a C-terminus which is unsubstituted or a C-termi-
nal amide represented by —C(O)NH,.
7. The method of claim 5, wherein the thrombin peptide
derivatives each comprise the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2), wherein
X, is Glu or Gln and X, is Phe, Met, Leu, His or Val, or a
fragment thereof, comprising amino acids 10-18 of SEQ ID
NO:2, the thrombin peptide derivatives each comprise an
N-terminus whichis unsubstituted, and a C-terminus which is
unsubstituted or a C-terminal amide represented by —C(O)
NH,the dimeris essentially free of monomer; the thrombin
peptide derivatives are the same, and the thrombin peptide
derivatives are covalently linked through a disulfide bond.
8. The method of claim 5, wherein the thrombin peptide
derivatives each comprise the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2), wherein
X, is Glu or Gln and X, is Phe, Met, Leu, His or Val, the
thrombin peptide derivatives each comprise an N-terminus
which is unsubstituted; and a C-terminus which is unsubsti-
tuted or a C-terminal amide represented by —C(O)NH,,the
dimeris essentially free of monomer; the thrombin peptide
derivatives are the same, and the thrombin peptide derivatives
are covalently linked through a disulfide bond.
9. The method ofclaim 8, wherein X, is Glu and X,is Phe.
10. The method of claim 5, wherein the peptide dimer
comprises two thrombin peptide derivatives, each with the
amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val (SEQ ID NO:6), wherein the thrombin peptide
derivatives are covalently linked by a disulfide bond.
11. The method of claim 5, wherein the peptide dimeris
represented by the following structural formula:
HH-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-N
N-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH>H
HN-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH).
H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-NH
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12. The method of claim 1 wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
13. The method of claim 5, wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
14. The method of claim 11, wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
15. A methodof treating radiation damage in a subject
comprising administering to the subject a therapeutically
effective amount of a 12 to 23 amino acid thrombin peptide
derivative comprising a serine esterase conserved sequence
and a thrombin binding domain having the sequence Arg-
Gly-Asp-Ala (SEQ ID NO:16).
16. The methodofclaim 15, wherein the thrombin peptide
derivative comprises an N-terminus which is unsubstituted
and a C-terminus which is unsubstituted or a C-terminal
amide represented by —C(O)NH,and the thrombin peptide
derivative comprises a polypeptide having the amino
sequence of Arg-Gly-Asp-Ala-Cys-X,-Gly-Asp-Ser-Gly-
Gly-Pro-X,-Val (SEQ ID NO:1), wherein X, is Glu or Gln
and X, is Phe, Met, Leu, His or Val.
17. The methodofclaim 15, wherein the thrombin peptide
derivative comprises the amino acid sequence of Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2),or a frag-
mentthereof, comprising amino acids 10-18 of SEQ ID NO:
2, whereinX, is Glu or Gln and X,is Phe, Met, Leu,His orVal
and the thrombin peptide derivative comprises an N-terminus
which is unsubstituted and a C-terminus which is unsubsti-
tuted or a C-terminal amide represented by —C(O)NH.
18. A method of treating radiation damage in a subject
comprising administering to the subject a therapeutically
effective amountofthe polypeptide H-Ala-Gly-Tyr-Lys-Pro-
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21. The method ofclaim 19, wherein the thrombin peptide
derivatives each comprise the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2), wherein
X, is Glu or Gln and X, is Phe, Met, Leu, His or Val, or a
fragment thereof, comprising amino acids 10-18 of SEQ ID
NO:2, the thrombin peptide derivatives each comprise an
N-terminus whichis unsubstituted, and a C-terminus which is
unsubstituted or a C-terminal amide represented by —C(O)
NH,,the dimeris essentially free ofmonomer; the thrombin
peptide derivatives are the same, and the thrombin peptide
derivatives are covalently linked through a disulfide bond.
22. The method ofclaim 19, wherein the thrombin peptide
derivatives each comprise the amino acid sequence Ala-Gly-
Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val (SEQ ID NO:2), wherein
X, is Glu or Gln and X, is Phe, Met, Leu, His or Val, the
thrombin peptide derivatives each comprise an N-terminus
which is unsubstituted; and a C-terminus which is unsubsti-
tuted or a C-terminal amide represented by —C(O)NH,,the
dimeris essentially free of monomer; the thrombin peptide
derivatives are the same, and the thrombin peptide derivatives
are covalently linked through a disulfide bond.
23. The method of claim 22, wherein X, is Glu and X,is
Phe.
24. The method of claim 19, wherein the peptide dimer
comprises two thrombin peptide derivatives, each with the
amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-
Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-
Phe-Val (SEQ ID NO:6), wherein the thrombin peptide
derivatives are covalently linked by a disulfide bond.
25. A method oftreating radiation damage in a subject
comprising administering to the subject a peptide dimerrep-
resented by the following structural formula:
0
HH-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-N
N-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH>
H
H
N-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH).
H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-N
H
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-
Gly-Gly-Pro-Phe-Val-NH, (SEQ ID NO:3).
19. A methodof treating radiation damage in a subject
comprising administering to the subject a peptide dimer com-
prising two 12 to 23 amino acid thrombin peptide derivatives
which, independently, comprise a serine esterase conserved
sequence and a thrombin binding domain having the
sequence Arg-Gly-Asp-Ala (SEQ ID NO:16).
20. The methodofclaim 19, wherein the thrombin peptide
derivatives each comprise an N-terminus which is unsubsti-
tuted; and a C-terminus which is unsubstituted or a C-termi-
nal amide represented by —C(O)NH.
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26. The method of claim 15, wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
27. The method of claim 19, wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
28. The method of claim 25, wherein the method further
comprises administering to the subject a therapeutically
effective amount of an angiogenic growth factor.
* * * * *
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